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ACTIVATABLE NANOPROBES FOR 
INTRACELLULAR DRUG DELIVERY 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application is related to U.S. Provisional Application 
No. 61,495,992 filed Jun. 11, 2011. Priority to this application 
is claimed under 35 USC § 119, and is incorporated herein. 
STATEMENT OF GOVERNMENT RIGHTS 
2 
FIG. 2a shows a Qdot fluorescence emission spectra ( exci-
tation wavelength: 375 nm) measured as a function of time at 
7.0 mM glutathione (GSH) concentration. These data show 
that full restoration of Qdot fluorescence occurs within one 
5 hour, after which no further increase in Qdot fluorescence 
intensity is observed. The inset shows a plot ofQdot fluores-
cence intensity measured at the peak emission wavelength 
(582 nm) as a function of time. This plot illustrates that the 
fluorescence intensity plateaus at 60 minutes. The (red) line 
10 of the plot is a non-linear fit to the data. 
The work leading to this invention was partly supported by 
grants from the NIH Grant No. 2P01HL059412-11Al and 
NSF Grant No. 0506560. Accordingly, the govermnent may 15 
have certain rights in the invention, as specified by law. 
FIG. 2(b) shows a STAT-3 fluorescence emission spectra 
(excitation wavelength: 300 nm) measured as a function of 
time at 7.0 mM GSH concentration. These data show that full 
restoration of STAT-3 fluorescence occurs within one hour, 
after which no further increase in STAT-3 fluorescence inten-
sity is observed. The inset shows a plot of STAT-3 fluores-
cence intensity measured at the peak emission wavelength 
(430 nm) as a function of time. This plot illustrates that the 
fluorescence intensity plateaus at 60 minutes. The (red) line 
FIELD OF THE INVENTION 
The present invention relates to the field of activatable 20 
nanoprobes, and in certain embodiments, to multifunctional 
activatable nanoprobes. 
of the plot is a non-linear fit to the data. 
FIG. 3a-3d includes phase-contrast (left panel) and corre-
sponding epi-fluorescence (right panel) microscopy images 
of: (a) MDA-MB-231 cells incubated with MMCNPs for 3 
hours, showing significant Qdot fluorescence. This confirms BACKGROUND OF THE INVENTION 
Cancer nanotechnology is a rapidly growing research area 
25 extensive folate receptor mediated uptake of the MMCNPs; 
(b) MDA-MB-231 cells incubated with MMCNPs for 24 
hours, again showing significant Qdot fluorescence that is 
similar to the 3 hour incubation experiment. These data show 
that uptake of MMCNPs and subsequent restoration of Qdot 
in nanomedicine involving disease diagnostics and 
therapy1 •2 . During the past decade, engineered nanoparticles 
integrated with multimodality/multifunctionality have 
enabled imaging of cancer cells with high sensitivity and 
demonstrated successful delivery of pre-loaded therapeutic 
drugs in a targeted manner3-7 . Multimodal nanoparticles that 
are integrated with optical and magnetic imaging modali-
ties8·9 have demonstrated strong potential to facilitate pre-
operative cancer diagnosis by MRI and optical based imag- 35 
ing10- 13 , to provide intra-operative surgical guidance (by 
optically demarcating tumor tissue from healthy tissue), and 
30 fluorescence (indicative of STAT-3 release) occurs in less 
than 3 hours; (c) control experiment performed with MDA-
MB-231 cells to which no MMCNPs were added. As 
expected only a minor cellular autofluorescence is observed; 
(d) control experiment performed with mouse thymus stro-
mal epithelial cells, TE-71 incubated with MMCNPs for 24 
hours. Similar to the control experiment shown in panel (c) 
only background autofluorescence is observed at locations 
that correspond to the locations of the cells, with no evidence 
of uptake ofMMCNPs by the TE-71 normal cells. This con-
trol experiment validates that the delivery of MMCNPs is 
highly targeted to MDA-MB-231 cells, which over-express 
to track tumor metastasis2 .7·8. 
Current nanoparticle technology allows for imaging of par-
ticles carrying therapeutic drugs3 •6 .7• 10•14•15 . However, no 40 
activatable drug delivery system has been reported to date that 
has demonstrated the ability to directly confirm intracellular 
drug release upon reaction with a cytosolic biomolecule. Up 
until now, challenges in designing and constructing a nano-
particle integrating imaging, monitoring, and therapeutic 45 
functionalities in a single unit have restricted the fabrication 
folate receptors. 
FIGS. 4a-4c shows: (a) bright field; and (b) corresponding 
epi-luminescence laser microscopy images ofMDA-MB-231 
cells incubated with MMCNPs for 5 hours. The bright spots 
in the fluorescence image indicate the location of aggregated 
of such a nanoparticle system. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The patent or application file contains at least one drawing 
executed in color. Copies of this patent or patent application 
publication with color drawing(s) will be provided by the 
Office upon request and payment of the necessary fee. 
FIG. la shows an optically activatable nanoprobe in an 
"off' state and an "on" state in accordance with an aspect of 
the present invention. 
FIG. lb is a TEM image of various activatable multifunc-
tional/multimodal composite nanoprobes (MMCNPs) show-
ing nearly spherical particles with irregular surface morphol-
ogy indicative of the presence of satellite quantum dots 
(Qdots) on the IONPs (iron oxide nanoparticle core). The size 
of the MMCNPs ranges from 20 nm to 40 nm, due to poly-
dispersity of IONPs. The inset shows a high magnification 
TEM image of a single MM CNP. The IONP can be discerned 
in the image by its light grey contrast while the Qdots 
appeared with dark contrast on the IONP surface. 
Qdots, revealing that the MMCNPs have reacted with intra-
cellular GSH. After this reaction, the GSH coated Qdots are 
somewhat hydrophobic innature leading to aggregation in the 
50 intra-cellular environment. Most of the aggregates as they 
appear in the bright field image (dark spots) and fluorescence 
image (corresponding bright spots) are localized near the cell 
membrane because of their hydrophobic nature. (c) Normal-
ized ensemble fluorescence emission spectra acquired by 
55 sample scanning laser confocal microscopy under 375 nm 
laser excitation. The ensembles are constructed by averaging 
fluorescence emission spectra obtained at different locations 
inside individual cells under illumination with a diffraction 
limited laser spots (-300 nm). Spectra were acquired at the 
60 location of the Qdot aggregates (red line) and the cellular 
regions without Qdots (autofluorescence, dark cyan line). As 
a control, the same experiment was completed for Qdots in 
the "OFF state" (black line) and "ON state" (blue line) on 
glass substrates. Both the intra-cellular and extra-cellular 
65 "ON state" Qdots appear slightly red shifted with respect to 
the "OFF state" Qdots. In addition, the "ON state" Qdots are 
significantly broadened at the blue edge as well as the red 
US 8, 791,285 B2 
3 
edge of the spectra, possibly due to the presence ofGSH on 
the Qdot surface. The difference in the appearance of the red 
shoulders in the intra-cellular and extra-cellular "ON state" 
Qdots is most likely due to the difference in the environment. 
The spectral feature around 500 nm in the intra-cellular "ON 5 
state" Qdot fluorescence emission ensemble spectrum is due 
the contribution of cellular autofluorescence. 
FIGS. Sa-d show: (a) a schematic of agar phantom design. 
The agar phantom consists of four layers. From bottom to top 
these layers are: MDA-MB-231 cellsembeddedinagar(con- 10 
trol), MMCNPs embedded in agar (control), MDA-MB-231 
cells loaded with the MMCNPs embedded in agar (sample) 
and agar layer, respectively. (b) a digital photograph of agar 
phantom; and ( c) a corresponding digital photograph of agar 
phantom under 366 nm multi band UV irradiation. The MDA- 15 
MB-231 cells loaded with the MMCNPs emit red fluores-
cence that is clearly visible to the naked eye. Control cells do 
not show any detectable fluorescence emission. (d) an MRI 
image ofagar phantom. The MDA-MB-231 cells loaded with 
the MMCNPs show strong MRI signal (indicated with false 20 
red color) in contrast with the control cells. 
FIG. 6 shows results from a CyQuant® cell viability assay 
performed on human breast (MB-MDA-231) and pancreatic 
(Pane- I) cancer lines, and mouse thymus stromal epithelial 
line, TE-71. Cells were untreated (Control) or treated for 24 25 
hours with MMCNPs to which no STAT-3 inhibitor was 
attached (RII 61), STAT-3 inhibitor only (Compound), and 
MMCNPs (RII 64). Compared to untreated (Control), the 
viability of cells treated with MMCNPs to which no STAT-3 
is attached (RII 61) was attached is not significantly different, 30 
indicating that the MMCNP itself do not compromise cell 
viability. By contrast, the cells treated with 50 µM STAT-3 
inhibitoronly (Compound) showed about a 15-20% decrease 
in cell viability, while cells treated with fully functional 
MMCNPs to which STAT-3 inhibitor was attached showed 35 
nearly 30% decrease in cell viability, even though the amount 
of STAT-3 inhibitor contained in the about 5 µg of MM CNP 
administered in about 100 µL of cell media was expected to be 
less than the about 50 µM that was directly added to the cells 
in the other study. This key observation demonstrates the 40 
effectiveness of the reported nanoparticle design in highly 
targeted drug delivery to the cancer cells while maximizing 
cancer cell death with reduced amounts of drugs used com-
pared to conventional approaches. Even though the MMC-
NP' s consume much less STAT3 drug, the delivery efficiency 45 
is dramatically increased, thus resulting in increased thera-
peutic efficiency while minimizing the potential for medical 
side effects due to the presence of excess free drug. 
FIG. 7 is a high resolution TEM (HRTEM) image of a 
single MMCNP. Individual satellite Qdots on the IONP sur- 50 
face can be clearly identified by their single crystalline struc-
ture while the IONP (iron oxide nanoparticle core) in the 
HRTEM image is obscured by the satellite Qdots. 
FIG. 8 shows FT-IR spectra of (a) dihydrolipoic acid, (b) 
lipoic acid, (c) dihydrolipoic acid coated IONPs, and (d) 55 
IONPs. The broad band at 3200-3600 cm-1 indicates the 
surface hydroxyl group of the super paramagnetic IONPs 
(Figure S4d). The bands at about 3046 (0-H), about 2934 
(--CH2-), about 1697 (C=O), about 1252 (0-H), and 
about 935 (OH) cm- 1 were observed for dihydrolipoic acid 60 
and lipoic acid in (a) and (b) respectively. The presence of 
these characteristic bands into the spectra of dihydrolipoic 
acid coated IONPs ( c) confirmed the dihydrolipoic acid coat-
ing on the surface ofIONPs. 
FIG. 9 shows normalized UV-Vis absorbance spectra of 65 
pure Qdots (red), IONP (black), Qdots attached to IONP 
(green) and MMCNPs (blue). After Qdots are attached to 
4 
IONPs, a large red shift of the absorption spectrum is 
observed, indicating successful attachment of satellite Qdots 
to IONP core. The attachment of STAT-3 to form MMCNPs 
leads to a narrowing of the UV-Vis spectrum and the slight 
blue shift in comparison to IONP-Qdot construct. 
FIG. 10 shows a normalized emission spectra of pure 
Qdots (red), IONP (black), Qdots attached to IONP (green) 
and MMCNPs (blue). Only a blue shift of the MMCNPs with 
respect to the free Qdots and the IONP-Qdot construct is 
observed. 
FIG.11showsa3D plot of the Qdot fluorescence intensity 
recovery from MMCNP ("OFF state") as a function of time 
for GSH concentrations ofabout 2.8, about 4.2, about 5 .7, and 
about 7 .0 mM. Even at the lowest GSH concentration, the 
Qdot fluorescence recovers in approximately 1 hour. Further-
more, the timescale of fluorescence recovery appears to be 
independent of GSH concentration higher than about 1.4 
mM. Since the intra-cellular concentration of GSH ranges 
from about 1 mM to about 15 mM, it is expected that 
MMCNP uptaken by the cancer cells will release its cargo 
intracellularly (e.g., drug) within about an hour. 
FIG. 12 is a TEM image of a plurality ofIONPs showing 
polydispersity. Bar=20 nm. 
FIG. 13 is a 3D reconstruction of MRI images recorded on 
agar phantom. This demonstrates the appearance of strong 
MRI signal from the MDA-MB-231 cells loaded with the 
MMCNPs (indicated with false red color). 
FIG. 14 shows another embodiment of an optically activat-
able nanoprobe (DNCP) in accordance with an another aspect 
of the present invention. 
FIG. 15 shows a plurality of STAT3 inhibitors for use with 
nanoparticles in accordance with an aspect of the present 
invention. 
FIG. 16 illustrates an exemplary NAC-modified STAT3 
inhibitor. 
FIG. 17 is a schematic illustrating sensing of cargo release 
by a Qdot core due to intracellular GSH. 
FIGS. l8a-b shows a nanoparticle having a CdS:Mn/ZnS 
quantum dot core, to which an S3I inhibitor drug will be 
covalently linked via a cleavable disulfide bond linkage. (a) a 
lipid bilayer may be overcoated on the surface of the S3I 
conjugated CdS:Mn/ZnS quantum dots. (b) the lipid bilayer 
may be further functionalized with folic acid to target cancer 
cells that overexpress folate receptors, or with TAT peptide (a 
cell-penetrating peptide). 
FIGS. l9a-c show (a) anAFM image of zwitterionic (DCS, 
9PC) lipid vesicles and chemical structures of ( b) DOTAP and 
(c) PtdEtn. 
FIG. 20 shows the effect of an increase of EDTA concen-
tration on the fluorescence intensity ofGSH-Qdot. 
FIG. 21 shows the effect of an increase of Cu ion concen-
tration on the fluorescence intensity ofGSH-Qdot. 
FIG. 22 shows the effect of an increase of EDTA concen-
tration on the fluorescence intensity of a NAC-Qdot. 
FIG. 23 shows the effect of an increase of Cu ion concen-
tration on the fluorescence intensity of a NAC-Qdot. 
DETAILED DESCRIPTION OF THE INVENTION 
The present inventors have developed new and unique acti-
vatable nanoprobes that may deliver active agents, and in 
some embodiments, may also be optically and magnetically 
imageable, targetable, and/or capable of reporting on intrac-
ellular drug release events. In one particular exemplary 
embodiment, an optically activatable nanoprobe is provided 
that comprises an inorganic core, e.g., a super-paramagnetic 
iron oxide nanoparticle core (IONP), associated with satellite 
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quantum dots (Qdots), e.g., CdS:Mn/ZnS quantum dots, 
where the Qdots themselves are further functionalized with 
6 
As used herein, the term "hydrophilic" refers to any sub-
stance having an affinity for water and tending to dissolve in, 
mix with, or swell in a water or aqueous medium. 
As used herein, the term "hydrophobic" refers to any sub-
stance not having an affinity for water and tending not to 
dissolve in, mix with, or swell in a water or aqueous medium. 
an active agent, a targerting agent, and a hydrophilic dispers-
ing agent. Advantageously, the Qdot luminescence is 
quenched in this nanoprobe ("OFF" state) due to combined 
electron/energy transfer mediated quenching processes 
involving IONP, targeting agent and active agents. Upon 
intracellular uptake, the nanoprobe is exposed to a cytosolic 
glutathione (GSH)-containing environment resulting in res-
toration of the Qdot luminescence ("ON" state), which 
reports on uptake and drug release. Probe functionality was 
validated using fluorescence and MR measurements, as well 
As used herein, the term "surfactant" refers to a wetting 
agent that lowers the surface tension of a liquid, thereby 
allowing easier spreading and the lowering of the interfacial 
10 tension between two liquids. 
As used herein, the term "STAT" refers to signal transduc-
ers and activators of transcription, which represent a family of 
proteins that, when activated by protein tyrosine kinases in 
the cytoplasm of the cell, migrate to the nucleus and activate as in vitro studies using cancer cells that overexpress folate 
receptors. 
It is important to an understanding of the present invention 
to note that all technical and scientific terms used herein, 
unless defined herein, are intended to have the same meaning 
15 gene transcription. 
In accordance with one aspect of the present invention, 
there is provided an activatable nanoprobe comprising a core 
component and an active agent associated with the core com-
ponent via a bond configured to be cleaved upon exposure to 
an endogenous compound. 
In accordance with one aspect, there is provided an acti-
vatable nanoprobe comprising a core component and an acti-
vatable active agent associated with the core component. A 
lipid vesicle at least partially or fully encases the activatable 
as commonly understood by one of ordinary skill in the art. 
The techniques employed herein are also those that are known 20 
to one of ordinary skill in the art, unless stated otherwise. 
Prior to setting forth the invention in detail and for purposes of 
more clearly facilitating an understanding the invention as 
disclosed and claimed herein, the following definitions are 
provided. 25 agent and the core component. 
As used herein, the terms "about" and "approximately" as 
used herein refers to-values that are ±10% of the stated 
value. 
In accordance with another aspect, there is an optically 
activatable nanoprobe comprising an inorganic core and a 
Qdot linked to the inorganic core. At least one ligand is linked 
to the Qdot. The one or more ligands, which are typically As used herein, the term "active agent" includes any syn-
thetic or natural element or compound, which when intro-
duced into a mammal causes a desired response, such as an 
optical or biological response. 
As used herein, the term "activatable" refers to an agent 
capable of being released from an associated substrate, e.g., 
core, upon exposure to a predetermined compound. For 
example and without limitation, an activatable active agent 
may include an active agent that is released from a core 
component upon exposure to an endogenous molecule, such 
30 electron-rich, are effective to reduce luminescence of the 
quantum dot when linked thereto. In this way, the Qdot lumi-
nescence is quenched in this nanocomposite probe ("off 
state") due to electron/energy transfer quenching processes 
between the inorganic core and the at least one ligand. In one 
35 embodiment, the at least one ligand comprises at least one of 
a biologically active agent, a targeting agent, a hydrophilic 
dispersing agent, or combinations thereof. 
In accordance with another aspect, there is provided an 
optically activatable nanoprobe for monitoring intracellular as glutathione, that cleaves a bond between the active agent 
and the core component. 
As used herein, the term "aptamer" refers to any oligo-
nucleic acid or peptide molecules that bind to a specific target 
molecule. 
40 drug delivery. The nanoprobe comprises a core component; 
and at least one ligand linked to the core component. The at 
least one ligand comprises at least one of an active agent, a 
targeting agent, an imaging agent, a hydrophilic dispersing 
agent, and combinations thereof. The at least one ligand is As used herein, the terms "chitosan" or "chitosan polymer" 
refer to chitosan (also known as poliglusam, deacetylchitin, 
poly-(D)glucosamine) and any derivatives thereof. The chi-
tosan polymer is typically composed of a linear polysaccha-
ride of randomly distributed ~-(1-4 )-linked D-glucosamine 
(deacetylated unit) and/or N-acetyl-D-glucosamine (acety-
lated unit) units. The general terms "chitosan" or "chitosan 50 
polymer" as used herein may also refer to chitosan or chitosan 
having one or more molecules attached thereto, e.g., bonded, 
45 effective to reduce luminescence of the quantum dot when 
linked thereto. 
or conjugated, thereto, such as an imaging agent, a target-
specific ligand, or a biologically active compound. Exem-
plary derivatives of chitosan include trimethylchitosan 55 
(where the amino group has been trimethylated) or quater-
nized chitosan. Advantageously, chitosan has a plurality of 
amine functional groups, which as set forth below, may be 
utilized for the attachment of various agents thereto, such as 
imaging agents, target-specific ligands, and/or biologically 60 
active agents. 
As used herein, "folate species" or "folate" refers to folate, 
folic acid, derivatives thereof, or analogs thereof. 
As used herein, the terms "bonded," "linked," "labeled," 
"attached," "conjugated," and variations thereof are intended 65 
to be used interchangeably and may refer to covalent, ionic, 
Van der Waals, or hydrogen bonding, for example. 
In accordance with another aspect, there is provided an 
optically activatable nanoprobe for monitoring intracellular 
drug delivery. The optically activatable nanoprobe comprises 
an inorganic core and a plurality of quantum dots linked to the 
inorganic core. A plurality of ligands are linked to respective 
ones of the plurality of quantum dots. The plurality ofligands 
include each of a biologically active agent, a targeting agent, 
and a hydrophilic dispersing agent. Since the ligands are 
electron rich, the ligands collectively reduce luminescence of 
the of the quantum dot when linked thereto. 
In accordance with another aspect, there is provided an 
optically activatable nanoprobe comprising a quantum dot 
core and at least one ligand linked to the quantum dot core. A 
chitosan-based shell surrounds the quantum dot core and the 
at least one ligand. 
In accordance with another aspect, there is provided a 
method for monitoring intracellular drug delivery within a 
subject. The method comprises administering to the subject 
an effective amount of an optically activatable nanoprobe. 
The optically activatable nanoprobe comprises an inorganic 
core, a plurality of quantum dots linked to the inorganic core, 
US 8, 791,285 B2 
7 8 
In yet another aspect, there is provided an optically acti-
vatable nanoprobe comprising a core component comprising 
a quantum dot; and a coating comprising a hydrophilic dis-
persing agent at least partially surrounding the core compo-
nent. 
and at least an active agent linked to the respective ones of the 
quantum dots. Upon intracellular uptake of the nanoprobe, a 
linkage between the active agents and the quantum dots is 
cleaved to allow the plurality of quantum dots to transfer from 
a quenched state, wherein the luminescence of the plurality of 
quantum dots is quenched, to a luminescent state, wherein the 
luminescence of the plurality of quantum dot is activated. In 
one embodiment, the method further comprises detecting a 
presence of the plurality of quantum dots, wherein an increase 
In certain aspects, the nanoprobes include a core compo-
nent. In one embodiment, the core component comprises an 
inorganic core, which allows for the attachment of a plurality 
of a Qdots to be disposed about the inorganic core. In this way, 
a single activatable nanoprobe may have a plurality of quan-
tum dots attached thereto for signal enhancement in monitor-
ing applications. In one embodiment, the inorganic core com-
prises a paramagnetic material. In a particular embodiment, 
in luminescence of the plurality of quantum dots is indicative 10 
of a release of the active agent intracellularly. In one embodi-
ment, the at least one ligand comprises each of an active 
agent, a targeting agent, an imaging agent, and a hydrophilic 
dispersing agent, or a combination thereof. 
15 
the inorganic core comprises iron oxide. A super-paramag-
netic iron oxide nanoparticle is an excellent MRI contrast 
agent (also called a T2 contrast agent). Utilizing iron oxide in 
the inorganic core facilitates imaging ofMMCNPs by MRI. It 
In yet another aspect, there is provided a method for moni-
toring intracellular drug delivery within a subject. The 
method comprises administering to the subject an effective 
amount of an optically activatable nanoprobe. The optically 
activatable nanoprobe comprises a core component compris- 20 
ing a quantum dot and an active agent linked to the quantum 
dot. Upon intracellular uptake of the nanoprobe, a linkage 
between the active agent and the core component is cleaved to 
allow for release of the active agent and to allow the quantum 
dot to transfer from a quenched state, wherein the lumines- 25 
cence of the plurality of quantum dot is quenched, to a lumi-
nescent state, wherein the luminescence of the plurality of 
quantum dots is activated. The method further comprises 
detecting a presence of the quantum dot, wherein an increase 
also assists in purification, as an external permanent magnet 
can be implemented to separate MMCNPs magnetically from 
the reaction mixture. 
The Qdots may comprise a semiconductor crystal whose 
size is on the order of just a few nanometers and that exhibits 
quantum confinement. Typically, Qdots contain anywhere 
from about 100 to about 1,000 essentially free electrons and 
range from about 2 nm to about 10 nm in size, or about 10 to 
about 50 atoms, in diameter. One of the optical features of an 
excitonic Qdot noticeable to the unaided eye is coloration. 
While the material which makes up a quantum dot is signifi-
cant, more significant in terms of coloration is the size. The 
larger the Qdot, the redder (the more towards the longer 
in luminescence of the quantum dot is indicative of a release 30 
of the active agent intracellularly. 
In yet another aspect, there is provided an activatable nano-
probe comprising a core component; an activatable active 
agent associated with the core component; and a lipid vesicle 
at least partially or fully encasing the activatable agent and the 35 
wavelength end of the electromagnetic spectrum) they fluo-
resce. The smaller the Qdot, the bluer (the more towards the 
short wavelength end) it is. The coloration is directly related 
to the energy levels of the Qdot. Quantitatively speaking, the 
band gap energy that determines the energy (and hence color) core component. 
In still another aspect, there is provided an optically acti-
vatable nanoprobe comprising: an inorganic core; a plurality 
of quantum dots about the inorganic core and linked to the 
inorganic core; and a hydrophilic dispersing agent linked to 
respective ones of a plurality of the quantum dots. 
In still another aspect, there is provided a method for mak-
ing optically activatable nanoprobes. The method comprises 
obtaining a plurality of nanoparticles comprising an inor-
ganic core and obtaining a plurality of quantum dots. Further, 
the method comprises linking the plurality of quantum dots to 
the inorganic core; and linking an active agent, a targeting 
agent, and a hydrophilic dispersing agent to respective ones of 
the plurality of quantum dots. 
In yet another aspect, there is provided a method for moni-
toring intracellular drug delivery within a subject in whom an 
effective amount of an optically activatable nanoprobe has 
been administered. The optically activatable nanoprobe com-
prises an inorganic core; a plurality of quantum dots linked to 
the inorganic core, and at least one ligand linked to respective 
ones of the plurality of quantum dots, the at least one ligand 
comprising at least an active agent linked to the quantum dot 
by a linkage; and wherein, upon intracellular uptake of the 
nanoprobe, a linkage between the active agent and a respec-
tive quantum dot is cleaved to allow for release of the active 
agent and to allow the plurality of quantum dots to transfer 
from a quenched state, wherein the luminescence of the plu-
rality of quantum dots is quenched, to a luminescent state, and 
wherein the luminescence of the plurality of quantum dot is 
activated. The method further comprises confirming release 
of the biologically active agent by detecting a presence of the 
plurality of quantum dots in the luminescent state. 
of the fluoresced light is approximately inversely propor-
tional to the square of the size of the Qdot. Larger Qdots have 
more energy levels, which are more closely spaced. This 
40 allows the Qdot to absorb photons containing less energy, 
e.g., those closer to the red end of the spectrum. 
In certain embodiments, the Qdots include a semiconduc-
tor nanocrystal core and a wide band-gap semiconductor 
nanocrystalline shell (coating) disposed on the surface of the 
45 nanocrystal core, which is typically different from the mate-
rial used for the nanocrystal core. The semiconductor coating 
may define a fully or partially passivating semiconductor 
coating layer. Exemplary materials for the nanocrystal core 
and the semiconducting coating of the quantum dot include, 
50 but are not limited to, zinc sulfide, zinc selenide, zinc tellu-
ride, cadmium sulfide, cadmium selenide, cadmium telluride, 
mercury sulfide, mercury selenide, mercury telluride, mag-
nesium telluride, aluminum phosphide, aluminum arsenide, 
aluminum antimonide, gallium nitride, gallium phosphide, 
55 gallium arsenide, gallium antimonide, indium nitride, indium 
phosphide, indium arsenide, indium antimonide, aluminum 
sulfide, lead sulfide, lead selenide, germanium, silicon, other 
group II-group VI compounds, group III-group V com-
pounds, group IV compounds, and alloys, compounds, or 
60 mixtures thereof. In one embodiment, the semiconductor 
coating has a band gap greater than the band gap of the 
nanocrystal core. In some embodiments, the core material can 
also be doped with one or more suitable dopants, such as 
manganese (Mn) or copper (Cu). In the examples below, a 
65 nanoprobe comprising an iron oxide nanoparticle core asso-
ciated with satellite CdS:Mn/ZnS Qdots was formed, 
although it is understood the present invention is not so lim-
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ited. In another embodiment, the Qdots may comprise ZnS: 
Mn/ZnS Qdots (non-heavy metal containing Qdots such as 
cadmium or arsenic). 
10 
The DNA aptamer sgc8c has been shown to have a particu-
lar binding affinity for leukemia cells, e.g, acute lymphoblas-
tic leukemia T-cells. 
In particular embodiments, a coupling agent may be pro-
vided to link the Qdots to the inorganic core. In one embodi- 5 
ment, the coupling agent comprises a heterobifunctional 
cross-linking compound that can link to the inorganic core at 
one location thereon and can link to a respective Qdot at a 
location thereon. In one embodiment, the coupling agent 
comprises dihydrolipoic acid (DHLA), which can link the 10 
inorganic core thereto through its carboxyl end and link to a 
respective Qdot via its bidentate thiol bonds. 
When the ligand comprises a hydrophilic dispersing agent, 
the hydrophilic dispersing agent may be directly or indirectly 
linked to respective ones of the quantum dots. In addition, 
when the ligand comprises a hydrophilic dispersing agent, the 
hydrophilic dispersing agent may comprise any compound 
that will increase a hydrophilicity of the nanoprobe relative to 
a nanoprobe without the hydrophilic dispersing agent. Exem-
plary hydrophilic dispersing agents include but are not lim-
ited to one or more of NAC (N-Acetyl-L-Cysteine (NAC), 
glutathione (GSH), PEG (polyethylene glycol), m-PEG, PPG 
(polypropylene glycol), m-PPG, PGA (polyglutamic acid), 
polysialic acid, polyaspartate, polylysine, polyethyelene-
imine, biodegradable polymers (e.g., polylactide, polyglyc-
Either or both of the inorganic core or the quantum dots can 
be modified with the coupling agent prior to addition of the 
other of the components. In one embodiment, the coupling 15 
agent is provided as a coating over the inorganic core. As set 
forth below, in one embodiment, to minimize the possibility eride ), and functionalized PEG, e.g., terminal-functionalized 
PEG, and structural analogues of any of the above com-
pounds. 
of cross-linking when using a coupling agent, e.g., DHLA, 
the addition of the modified inorganic core particles to 
unmodified quantum dots may be done slowly and in a con- 20 
trolled manner. 
In one embodiment, the hydrophilic dispersing agent is 
indirectly linked to respective ones of the quantum dots 
through a spacer or linking compound. For example, as will 
be explained below, in a particular embodiment, a NAC 
(N-Acetyl-L-Cysteine )-modified ethylenediamine ligand 
When the ligand comprises a targeting agent, the targeting 
agent may be any compound having an affinity for a prede-
termined molecular target. In one embodiment, the targeting 
agent comprises a folate species, which may be folate, folic 
acid, or derivatives thereof. Examples of folate derivatives 
include, but are not limited to, dihydrofolate, tetrahydro-
folate, S-methyl-tetrahydrofolate and S,10-methylene tet-
rahydrofolate. Humans and other manmials express a number 
of proteins that bind to folate and transport it into cells. For 
example, in humans, alpha and beta folate receptors have 
been identified, each of which can occur in several isoforms 
(e.g. as a result of differential glycosylation). These proteins 
are referred to as "folate receptors." Thus, a folate receptor is 
considered to be any protein expressed on the surface of a cell, 
such as a cancer cell, which binds folate in preference to other 
moieties or compounds. In one embodiment, the targeting 
agent is selected to specifically target these folate receptors in 
a mammalian subject. 
Additionally, in other embodiments, the targeting agent 
may be one or more of an aptamer, a peptide, an oligonucle-
otide, an antigen, an antibody, or combinations thereofhaving 
an affinity for a predetermined molecular target. In one 
embodiment, the predetermined molecular target is associ-
ated with a cancer cell, a leukemia cell, an acute lymphoblas-
tic leukemia T-cell, or combinations thereof. In a particular 
embodiment, the ligand comprises an aptamer having an 
affinity for leukemia cells, e.g., an acute lymphoblastic leu-
kemia T-cell. The aptamer may include any polynucleotide-
or peptide-based molecule, for example. A polynucleotidal 
aptamer is a DNA or RNA molecule, usually comprising 
several strands of nucleic acids that adopt highly specific 
three-dimensional conformation designed to have appropri-
ate binding affinities and specificities towards specific target 
molecules, such as peptides, proteins, drugs, vitamins, among 
other organic and inorganic molecules. Such polynucleotidal 
aptamers can be selected from a vast population of random 
sequences through the use of systematic evolution ofligands 
by exponential enrichment. A peptide aptamer is typically a 
loop of about 10 to about 20 amino acids attached to a protein 
scaffold that bind to specific ligands. Peptide aptamers may 
be identified and isolated from combinatorial libraries, using 
methods such as the yeast two-hybrid system. In one embodi-
ment, the ligand comprises the DNA aptamer sgc8c having a 
sequence according to SEQ. ID No. 1: 
S'-ATC TAA CTG CTG CGC CGC CGG GAAAAT ACT 
GTA CGG TTA GA-3'. 
25 (NAC-EDA modified ligand) is first linked to the quantum dot 
surface via the sulfide groups ofNAC. Thereafter, the surface 
amine groups provided by NAC-EDA may be reacted with an 
N-hydroxysuccinimide (NHS) ester derivative of methyl-
poly-ethylene glycol (MPEG-NHS ester) to improve overall 
30 dispersability of the nanoprobe. 
In a particular embodiment, a plurality of hydrophilic dis-
persing agents are linked to a plurality of the Qdots so as to 
define a hydrophilic shell or coating for the nanoprobe. In one 
embodiment, a hydrophilic shell or coating is formed by 
35 linking a plurality of hydrophilic dispersing molecules to a 
plurality of Qdots surrounding the inorganic core. It is appre-
ciated that other ligands may be attached to the Qdots as 
described herein, e.g., an active agent or a target agent, and 
that the hydrophilic shell or coating may not be continuous. 
40 Typically, the coating or shell will at least partially surround 
the inorganic core. In one embodiment, the hydrophilic dis-
persing agent comprises GSH. In another embodiment, the 
hydrophilic dispersing agent comprises NAC. As set forth in 
the Example, the present inventors have found that GSH and 
45 NAC are at least capable of coating a Qdot surface via con-
jugation through their sulfhydryl (-SH) groups, and thus 
form "hydrophilic Qdots" or "hydrophobic nanoprobes." 
Both GSH-Qdots and NAC-Qdots, and particularly NAC-
Qdots, may be an attractive choice for the fabrication of 
50 activatable ("OFF/ON") Qdots for bioimaging and sensing 
applications. 
When the ligand of the optically activatable nanoprobe 
comprises an active agent, the active agent may include any 
compound or composition that produces a preventative, heal-
55 ing, curative, stabilizing, ameliorative or other beneficial 
therapeutic effect. In a particular embodiment, the active 
agent is a STAT inhibitor, such as a STAT-3 inhibitor. 
Examples of manmialian STAT inhibitors include inhibitors 
ofSTAT-1, STAT-2, STAT-3, STAT-4, STAT-Sa, STAT-Sb, and 
60 STAT-6. In one embodiment, the active agent is one or more 
ofBP-1-102, SF-1066 and S31-201, all of which have proven 
activity against STAT-3 with IC50 values of 6.8, 3S, and 86 
µm, respectively. 
STAT-3, in particular, is an oncogene constitutively acti-
65 vated in many cancer systems where it contributes to carcino-
genesis. The signal transducers and activators of transcription 
(STATs) are a class of transcription factor proteins that regu-
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late cell growth and survival. A total of seven STAT isoforms, 
encoded in distinct genes, have been identified in mammalian 
cells. STAT-3 protein isoform is known to directly up-regulate 
Bcl-xL, Mcl-1, cyclin Dl/D2 and c-myc, contributing to 
compromised regulation by stimulating cell proliferation and 5 
preventing apoptosis in numerous human cancers including 
breast, prostate, melanoma, lung, brain, pancreatic, ovarian, 
colon cancers. STAT-3 activation occurs via phosphorylation 
of tyrosine 705, which promotes STAT dimer formation 
through STAT phosphotyrosine-SH2 domain interactions. 10 
These STAT dimers translocate to the nucleus, where they 
regulate gene expression. Constitutive STAT-3 activity medi-
ates dysregulated growth and survival, angiogenesis, as well 
as suppresses the host's immune surveillance of tumors and 
represents a valid target for small molecule anti-cancer 15 
design. The STAT-3 inhibitor for use in the present invention 
may be any known inhibitor of STAT3 known in the art. 
Exemplary STAT3 inhibitors are disclosed in U.S. Published 
Patent Application Nos. 20100310645, 20090318367, 
20090069420, 20080187992, 20070123502, 20050074502, 20 
and 20050004009, the entirety each of which is incorporated 
12 
4,7-tryl)triaceticacid). Gd3 + ions are paramagnetic and 
DOTA is a chelator of Gd ion. The Gd-DOTA is paramagnetic 
agent and it provides MRI contrast. Gd-DOTA is commer-
cially available under the brandname ProHance® (also called 
Gadoteridol). In another embodiment, the imaging agent may 
comprise iohexyl. 
In accordance with one aspect of the invention, the 
ligand(s) (e.g., a targeting agent, dispersing agent, and/or an 
active agent), the cross-linker or spacing compound, and/or 
the Qdot may be modified with a compound that increases the 
functionality and/or dispersability of the optically activatable 
nanoprobe in aqueous solutions, particularly at pH of 7.4. In 
one embodiment, the ligand(s) (e.g., a targeting agent, dis-
persing agent, and/or an active agent), the linking or spacing 
compound, and/or the quantum dot may be modified with 
NAC (N-Acety 1-L-Cysteine ). NAC-modification of the Qdot, 
ligand, or linking/spacing molecules has several advantages: 
(i) NAC passivates the Qdot surface via formation of stable 
disulfide bonds, resulting in increased quantum efficiency; ii) 
NAC improves aqueous dispersability of the nanoprobes; and 
iii) NAC provides surface carboxyl groups for functionaliza-
tion with other desired ligands. 
The below description further describes exemplary 
embodiments of an optically activatable nanoprobe in accor-
by reference herein. Typically, the STAT-3 inhibitor will 
include a sulfur-containing functional group, which may 
form a covalent disulfide bond with the Qdot to form a linkage 
between the STAT-3 inhibitor and the Qdot. 
The optically activatable nanoprobes described herein may 
thus be utilized to monitor and/or treat any proliferation dis-
order characterized by the over-activation of a STAT protein. 
25 dance with the present invention and a method for making the 
same. It is understood that the present invention, however, is 
not limited to the below-described optically activatable nano-
probes, and that the nanoprobes may include one, two, or 
In one embodiment, the proliferation disorder to be treated is 
a cancer producing a tumor characterized by over-activation 30 
of STAT!, STAT3, STATS, or a combination of two or all 
three of the foregoing. Examples of such cancer types 
include, but are not limited to, breast cancer, ovarian cancer, 
multiple myeloma and blood malignancies, such as acute 
myelogenous leukemia. In addition to cancer, the prolifera- 35 
tion disorder to be treated using the compounds, composi-
tions, and methods of the invention can be one characterized 
by aberrant STAT-3 activation within cells associated with a 
non-malignant disease, pathological state or disorder ( collec-
tively "disease"), and likewise comprising administering or 40 
contacting the cells with a an effective amount of one or more 
STAT3 inhibitors to reduce or inhibit the proliferation. 
In still other embodiments, the active agent may include 
peptides (e.g., RGD peptide, integrin selective; see 
Dechantsreiter, M.A., et al., N-Methylated Cyclic RGD Pep- 45 
tides as Highly Active and Selective av~3 Integrin Antago-
nists. Journal of Medicinal Chemistry, 1999. 42(16): p. 3033-
3040.), antibodies (e.g., CDlO monoclonal antibody for 
targeting human leukemia; see Santra, S., et al., Conjugation 
of Biomolecules with Luminophore-Doped Silica Nanopar- 50 
ticles for Photostable Biomarkers. Analytical Chemistry, 
2001. 73(20): p. 4988-4993.) and proteins. When the opti-
cally activatable nanoprobes comprise a biologically active 
drug, as well a target-specific ligand, the disclosed nano-
probes are useful as target-specific drug delivery vehicles. 55 
The imaging agent may comprise one or more of a fluoro-
phore, iohexy 1, and a paramagnetic chelate having a paramag-
netic ion bound therein. In another embodiment, the imaging 
agent may be a fluorophore and/or a paramagnetic chelate 
( chelator) having an MRI (magnetic resonance imaging) con- 60 
trast agent bound therein. The MRI contrast agent may com-
prise a paramagnetic ion selected from one or more of gado-
linium, dysprosium, europium, and compounds, or 
combinations thereof, for example. In one embodiment, the 
paramagnetic ion comprises a gadolinium ion and the chela- 65 
tor is a DOTA-NHS ester (2,2',2"-(10-(2-(2.5-dioxopyrroli-
din-1 yloxy)-2-oxoethyl)-14, 7, 1 O-tetraazacyclododecane-1, 
more of the ligands described below attached to the Qdots, 
may include other linked compounds, and may be further 
modified as necessary for the particular application. 
In one embodiment, as shown in FIG. la, the optically 
activatable nanoprobe (MMCNP) comprises a super-para-
magnetic ironoxidenanoparticle core (IONP; -5-20 nm size) 
and satellite CdS:Mn/ZnS quantum dot (Qdots; -3.5 nm size) 
shell. Each Qdot is attached to the core IONP by a hetero-
bifunctional cross-linker molecule, dihydrolipoic acid 
(DHLA). The DHLA connects the IONP through its carboxyl 
end and to the Qdot via its bidentate thiol bonds. To minimize 
the possibility of cross-linking, the IONP-Qdot conjugation 
strategy involved controlled addition of DHLA modified 
IONP to unmodified Qdots as described in the Example 
below. The carboxyl and the thiol functional groups are com-
patible with the IONP and Qdot particle surfaces, respec-
tive1s.24-26. 
Upon attachment of a Qdots to an IONP nanocrystal, a 
large surface area still remains available on the satellite Qdots 
for further surface modification and conjugation. Next, an 
N-Acetyl-L-Cysteine (NAC)-modified STAT3 inhibitor 
(NAC-STAT3; a therapeutic model drug), a NAC-modified 
fol ate (NAC-F A; a cancer targeting agent) and an NAC-modi-
fied ethylenediamine (NAC-EDA, an amine modified ligand) 
were separately synthesized. As set forth above, NAC-medi-
ated surface modification ofQdots has several advantages: (i) 
it passivates the Qdot surface via formation of stable disulfide 
bonds, resulting in increased quantum efficiency, (ii) it 
improves aqueous dispersibility ofQdots, and (iii) it provides 
surface carboxyl groups for functionalization with other 
desired ligands. Furthermore, this approach reflects the 
uniqueness of the reported MMCNP design, where the sepa-
rate synthesis of each of these ligands allows for control of the 
ratio of these ligands when attaching to Qdots or substitution 
of one of these ligands, resulting in a fully modular design of 
the MMCNP (akin to a nanoparticle LEGO®). After IONP-
Qdot conjugation, further surface conjugation reactions were 
performed by treating IONP-Qdot with a mixture of NAC-
STAT3, NAC-FA and NAC-EDA. The surface modification 
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procedures are detailed in Examples below. The surface 
amine groups (provided by NAC-EDA) were reacted with the 
N-hydroxysuccinimide (NHS) ester derivative of methyl-
poly-ethylene glycol (MPEG-NHS ester; a biocompatible 
highly-hydrophilic dispersing agent) to improve overall dis- 5 
persibility of the MMCNPs. 
A STAT-3 drug and folate (FA) were intentionally selected 
as electron-rich ligands that can substantially quench Qdot 
fluorescence. Substantial quenching typically refers to 
75-100% quenching of fluorescence. In a more specific 10 
embodiment, substantial quenching refers to 90-100% fluo-
rescence quenching. This selection process involved mixing 
of each of these ligands with Qdots followed by observation 
of the extent of luminescence quenching (data not shown). 
Each of these ligands thus serves a dual purpose. The treat- 15 
ment ofIONP-Qdots with NAC-STAT3 and NAC-FA drasti-
cally reduced the fluorescence of the Qdots. It was noted that 
NAC itself did not quench Qdot luminescence, thus justifying 
the combined role ofSTAT-3 drug and FA as quenchers. As a 
result, the MM CNP is essentially in a fluorescently quenched 20 
("OFF") state when the ligand(s) are attached to the Qdots. It 
is understood that by "OFF," however, it is not necessarily 
meant the nanoprobe is 100% quenched or does not exhibit 
some luminescence, but only that the amount of lumines-
cence is greater when the ligand(s) are not attached vs. 25 
attached. The luminescence of the MMCNPs is restored 
("ON" state) upon treatment with an appropriate cleaving 
agent, which effectively cleaves disulfide bonds between the 
ligand and the IONP-Qdots, such as glutathione (GSH). 
The morphological, optical, and magnetic properties of 30 
MMNCPs were extensively characterized. TEM studies con-
firm the formation of about 20-40 nm size nanocomposites as 
shown in FIG. lb. The IONP core and satellite Qdots sur-
rounding the core are clearly visible with low resolution TEM 
(FIG. lb), whereas magnified TEM images clearly show 35 
Qdots around the IONP (FIG. lb inset). HRTEM also con-
firms the single crystalline structure of the Qdots (FIG. 7) 
surrounding the core IONP. Inductively coupled plasma 
analysis of the sample confirms the presence of Zn (about 41 
wt%), Fe (about 6.2 wt%) and Cd (about 10 wt%) with a 40 
relative ratio of about 6.6: 1.0: 1.6 (WAN). Zeta potential (s) 
measurements correlate with particle surface charge. The I; 
values ofIONP, IONP-DHLA, IONP-Qdots-STAT3-FA and 
IONP-Qdot-STAT3-FA-m PEG are about -20 mV, about 
-4.0 mV, about -17 mV and about -21 mV, respectively. As 45 
expected, DHLA modification of the iron oxide nanoparticle 
core (IONP) drastically reduced its surface charge due to 
reduction of the negative surface charge of the IONP. Further 
surface modification with the STAT-3 drug and folic acid 
(folate) resulted in an increase in the overall negative surface 50 
charge on the particle. This is likely due to the presence of 
carboxyl groups on the folate residues on the particle surface. 
Pegylation with biocompatible mPEG, however, showed 
minimal effect on the particle surface charge due to its neutral 
nature. It was observed that pegylated particles exhibited 55 
good phosphate buffer dispersibility. A comparative analysis 
of FT-IR spectra of dihydrolipoic acid (DHLA) (a), lipoic 
acid (b ), DHLA-coated IONPs ( c ), and IONPs ( d) confirmed 
successful surface modification of IONP with DHLA (FIG. 
8). Fluorescence spectroscopy in solution was used to inves- 60 
tigate the Qdot luminscence properties at different stages of 
MM CNP development as well as for tracking the drug release 
events. 
14 
tathione disulfide (GSSG), its oxidized form. 29 The design of 
the MMCNPs is such that once they are exposed to an intra-
cellular GSH environment, the nanoprobes will break apart 
into its different constituents that make up the composite 
nanoprobes. This forms the basis of the intracellular tracking 
of the STAT-3 drug release as schematically shown in FIG. 
la. Distinct changes in absorption spectra were observed for 
IONP-Qdot and IONP-Qdot-STAT3 conjugates in compari-
son to Qdots (FIG. 9). The Qdot absorption spectrum broad-
ens significantly and slightly shifts towards longer wave-
length when conjugated to IONPs. However, upon further 
conjugation with NAC-STAT3 drug, NAC-FA and NAC-
EDA, a decrease in spectral width along with slight blue shift 
was observed with respect to the IONP-Qdots conjugates. 
Such changes in absorption spectral characteristics support 
successful surface conjugation of Qdots with IONP, STAT3 
drug and FA. The emission of MM CNP is slightly blue shifted 
compared to either Qdots or IONP-Qdot conjugates (FIG. 
10). 
Fluorescence data acquired by adding GSH to MMCNPs in 
solution show that Qdot fluorescence can be substantially 
restored in less than one hour (FIGS. 2a and 2b). Further-
more, a systematic study on the effect of GSH concentration 
on the time scale of fluorescence restoration shows that there 
is no significant effect of varying GSH concentrations in the 
range of 2.8 mM to 7 mM (FIG. 11). The observed spectral 
features of the "ON" state Qdots (i.e. after release from 
MMCNP) (FIG. 2a) are in good agreement with those of 
Qdots in solution as shown in FIG. 10. The STAT-3 inhibitor 
is also a fluorescent molecule O'-ex: 300 nm and "-em: 396 nm) 
of which the fluorescence is substantially quenched in MMC-
NPs. Fluorescence quenching of STAT-3 drug is presumably 
due to electron/energy transfer from STAT-3 to Qdots. It is 
unlikely that the IONP will have any significant contribution 
towards STAT-3 fluorescence quenching as STAT-3 is not 
directly attached to IONP surface. Restoration of STAT-3 
drug emission is observed once MMCNPs are treated with 
GSH in solution (FIG. 2b ), thus confirming disintegration of 
MMCNPs and release of STAT-3 inhibitors. 
To confirm the effectiveness of the optically activatable 
nanoprobes (MMCNPs), the MMCNPs were challenged 
against the intracellular GSH environment where the reported 
GSH concentration is in the millimolar (mM) range, typically 
between about 2 mM and about 15 mM27•28 . The human 
breast cancer (MDA-MB-231) cell line, known to over-ex-
press folate receptors30 , and the mouse thymus stromal epi-
thelial cell line (TE-71) were incubated forup to 24 hrs with 
MM CNP at a concentration of about 50 µg/mL. As expected, 
a significant uptake of folate conjugated MMCNPs by the 
cancer cells was observed compared to normal cells as shown 
in FIG. 3. These results also show that substantial restoration 
of fluorescence occurs within 3 hr incubation. Restoration of 
fluorescence in cancer cells is a direct confirmation of tar-
geted cellular uptake of MMCNPs and subsequent dispersal 
ofMMCNPs into its separate components, e.g., IONP, Qdots, 
and the release of ligands, including drug molecules. 
Systematic optical studies were performed to investigate 
intracellular drug release at the single cell level. Confocal 
microscopy images of the MDA-MB-231 cells incubated 
with MMCNPs for 5 hrs (FIGS. 4a-4c) clearly show that 
MMCNPs were uptaken by the cells. In addition, strong fluo-
rescence signal from only a few locations in the cell can be 
observed. These data show that Qdots were released from the 
MMCNP through the cleavage of disulfide bonds by GSH Glutathione (GSH), a tripeptide biomolecule found in all 
animal cells at relatively high cytosolic concentration (about 
1-10 mM27•28 , reduced form), effectively reduces disulfide 
bonds and in this process glutathione is converted to glu-
65 (see FIG. la). Besides the images of single cells incubated 
with MMCNPs, emission spectra of different regions in 
single cells were also collected (FIG. 4c, red and cyan lines). 
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The Qdots in the intracellular environment show emission 
spectra that are red-shifted and broadened with respect to 
uncoated free Qdots in solution (FIG. 10). These spectral 
differences are attributed to aggregation of the Qdots after 
release from MMCNP in the cytosol. This observation was 5 
confirmed with solution experiments on bare Qdots by 
observing emission spectra before and after aggregation, as 
well as addition of GSH to each of these samples (data not 
shown). 
It was found from control experiments that addition of 10 
GSH to a suspension of bare Qdots leads to a stable Qdot 
suspension and has no noticeable effect on the Qdot emission 
properties (data not shown). These observations may provide 
preliminary indication that in the intracellular environment 
GSH does not necessarily exchange with the NAC/cargo- 15 
ligand that is initially present on the Qdot surface due to the 
fact that intracellular Qdot aggregation is observed after 
cargo release, although it could be argued that binding con-
stants of both molecules could be comparable given that GSH 
and NAC both contain a single thiol group in their structure 20 
(monodentate ligand). 
The observation of only a few bright spots in a single cell in 
the fluorescence images indicates aggregation of multiple 
Qdots in a single or a few clusters. The Qdot aggregation is 
reasonable given that while in the MMCNP, Qdots are stabi- 25 
lized by PEG. After exposure to GSH, the PEG is removed by 
cleavage of disulfide bonds, resulting in hydrophobic Qdots 
that self-aggregate. In addition, the data shows that these 
Qdot aggregates preferentially localize near the cell mem-
brane, again due to their hydrophobic nature. Other locations 30 
where Qdot aggregates are not present only show autofluo-
rescence. It should be noted that while the STAT3 drug itself 
is typically also fluorescent (FIG. 2b), experiments on intra-
cellular delivery cannot be reliably performed by measuring 
the STAT3 drug fluorescence due to weak fluorescence and 35 
the presence of cellular auto-fluorescence, hence the need for 
the optical signal of the Qdots. 
To demonstrate the concept of multimodality of the MMC-
NPs, an agar phantom was prepared using a 10 mm NMR tube 
(FIGS. Sa-Sd) for MRI and optical imaging studies. FIG. Sa 40 
shows the schematic of agar phantom design. The bottom part 
of the tube contains only MDA-MB-231 cells (as a control), 
middle part contains only MMCNPs (as a control) and the top 
part of the tube contains the same cells loaded with MMC-
NPs. All of these were dispersed in 3% agarose gel under 45 
same condition. A digital image of the tube was recorded 
under room light (FIG. Sb) as well as under illumination by a 
hand-held 366 nm multiband UV lamp (FIG. Sc). The unfil-
tered images clearly show a light brown color where cells are 
located in room light conditions whereas an intense red color 50 
appears due to Qdot fluorescence under UV illumination. The 
MDA-MB-231 cells loaded with theMMCNPs emit red fluo-
rescence that is clearly visible to the naked eye. Control cells 
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that MMCNPs (with STAT-3) treated cancer cells have lower 
viability than cells treated with free STAT-3 drug when 
MMCNPs and STAT-3 were administered to the cell medium 
at identical concentrations. This finding is highly significant 
given that free STAT3 drug alone in medium is in high excess 
compared to STAT-3 drug present in MMCNPs under these 
conditions. Even though the MMCNPs consume much less 
S TAT3 drug, the delivery efficiency is dramatically increased, 
thus resulting in increased therapeutic efficiency while mini-
mizing the potential for medical side effects due to presence 
of excess free drug. 
In view of the above, a new and unique quantum dot 
(Qdot)-iron oxide (IO) based multimodal/multifunctional 
nanocomposite probe that is optically and magnetically 
imageable, targetable and capable of reporting on intracellu-
lar drug release events has been described herein. By design, 
the present nanoparticle system has multimodalities (opti-
cally and magnetically active) and multifunctionalities (i.e. 
imaging, targeting, drug delivery) that are current state-of-
the-art in nanomedicine research1 •8 •10•14- 16•18•23 - 26 . In addi-
tion, the MM CNP discussed here integrate sensing modalities 
that report on the event as well as the location ofintra-cellular 
release of cargo (drug, etc.). The impact and implications of 
this new development along with the traditional multimodali-
ties and multifunctionalities are immediate for drug discov-
ery and cancer biology. 
In accordance with another aspect, there is provided a 
method for monitoring intracellular drug delivery within a 
subject using any embodiment of an optically activatable 
nanoprobe described herein. In one embodiment, the method 
comprises administering to the subject an effective amount of 
a nanoprobe comprising an inorganic core and a plurality of 
quantum dots linked to the inorganic core. A ligand compris-
ing at least an active agent is linked to respective ones of the 
plurality of quantum dots. Upon intracellular uptake of the 
nanoprobe, the linkage between the active agent and the 
ligand is cleaved to allow release of the active agent and to 
allow the plurality of quantum dots to transfer from a 
quenched state, wherein the luminescence of the plurality of 
quantum dots is quenched, to a luminescent state, wherein the 
luminescence of the plurality of quantum dot is activated. In 
one embodiment, the linkage between the bioactive agent and 
the quantum dot is cleavable by intracellular glutathione 
(GSH). 
In a particular embodiment, the ligand may further com-
prise a targeting agent and a hydrophilic dispersing agent. For 
example, the active agent may comprise a STAT3 inhibitor, 
the targeting agent may comprise folate, and the hydrophilic 
dispersing agent may comprise m-polyethylene glycol 
(mPEG) or derivatives thereof. In addition, optionally, the 
bioactive agent, targeting agent, and the hydrophilic dispers-
ing agent may be modified with N-Acetyl-L-Cysteine to pro-
vide improved dispersability of the nanoprobes and addi-
tional functional groups for the attachment of desired ligands. 
In addition, the above-described method may further com-
prise the step of detecting a presence of the plurality of quan-
tum dots, wherein an increase in luminescence of the quan-
tum dots is indicative of a release of the active agent 
intracellularly. The detecting may be done by any suitable 
do not show any detectable fluorescence emission. An MRI 
image of the phantom (FIG. Sd) clearly shows cell clusters 55 
that correlate well with the fluorescence image. A 3D recon-
struction of the MR images is provided in FIG. 13. This 
demonstrated the appearance of strong MRI signal from the 
MDA-MB-231 cells loaded with the MMCNPs (indicated 
with false red color) in contrast with the control cells. 60 detection method known in the art appropriate for the particu-
lar type of Qdot. For example, the detection may be done by 
any one or more of transmission electron microscopy (TEM), 
scanning electron microscopy (SEM), dynamic light scatter-
ing (DLS), UV-visible (UV-VIS) spectroscopy, Fouriertrans-
A CyQUANT™ cell proliferation assay was used in a 
comparative cell viability study to determine cytotoxicity of 
MMCNPs without STAT-3 drug (control particle), STAT-3 
drug itself, and MMCNPs with STAT-3 conjugation. Two 
cancer cell lines, MDA-MB-231 and pancreatic (Pane- I) can-
cer cells were used along with mouse thymus stromal epithe-
lial TE-71 cells (control). Results (shown in FIG. 6) suggest 
65 form infrared spectroscopy (FTIR), zeta potential, high pres-
sure liquid chromatography-mass spectrometry (HPLC-MS), 
NMR/IR, mass spectrometry (MS), fluorescence excitation 
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and em1ss10n spectroscopy and fluorescence microscopy, 
near infrared (NIR) imaging (NIRS), and magnetic resonance 
(MR) imaging and spectroscopy 
The administering to the subject, who may be any mam-
malian subject, may be done according to any suitable route 
of in vivo administration that is suitable for delivering the 
composition into the subject. The preferred routes of admin-
istration will be apparent to those of skill in the art, depending 
18 
rescence. The restoration of Qdot fluorescence will take place 
when intracellular GSH acts upon the DCNP, cleaving the 
disulfide bond and releasing STAT3 drug from the DNCP 
core into the cytosol. Restoration of fluorescence typically 
involves at least a noticeable increase of fluorescence from a 
substantially quenched state. 
In one embodiment, a chitosan-based shell surrounds the 
Qdot core and any chemical entities attached thereto in the 
DCNPs. In one embodiment, the chitosan-based shell com-on the medium, the targeting agent (if present) or the active 
agent. Exemplary methods of in vivo administration include, 
but are not limited to, intravenous administration, intraperi-
toneal administration, intramuscular administration, intran-
odal administration, intracoronary administration, intraarte-
rial administration (e.g., into a carotid artery), subcutaneous 
administration, transdermal delivery, intratracheal adminis-
tration, intraarticular administration, intraventricular admin-
istration, inhalation (e.g., aerosol), intracranial, intraspinal, 
intraocular, intranasal, oral, bronchial, rectal, topical, vagi-
nal, urethral, pulmonary administration, impregnation of a 
catheter, and direct injection into a tissue. 
10 prises a chitosan polymer and a hydrophilic dispersing agent. 
Chains of the chitosan polymer electrostatically interact with 
chains of the hydrophilic dispersing agent to form an 
entangled network comprising the chitosan polymer and the 
hydrophilic dispersing agent. While not wishing to be bound 
15 by theory, it is believed that the chitosan-based shell will 
effectively scavenge ion leakage, e.g., cadmium ion leakage, 
from the Qdot core by forming a metal-ligand complex and 
will passivate cytotoxicity. When a plurality of active agents 
(e.g., a STAT-3 inhibitor) are attached to the Qdot core, the 
In accordance with another aspect, there is provided a 
method for making optically activatable nanoprobes as 
described herein. The method comprises obtaining a plurality 
20 plurality of active agents may be released intracellularly upon 
cleavage of the bond between the active agents and the Qdot 
of nanoparticles comprising an inorganic core, e.g., iron 
oxide core; obtaining a plurality of quantum dots; linking the 25 
plurality of quantum dots to the inorganic core; and linking at 
least one ligand to respective ones of the plurality of quantum 
dots, wherein the at least one ligand comprises an active 
agent, a targeting agent, or a hydrophilic dispersing agent. In 
core. 
The hydrophilic dispersing agent of the chitosan-based 
shell may be any compound having repeating structural units 
that have one or more functional groups that will interact by 
electrostatic or charge attraction (or otherwise) with the 
amine functional groups of the chitosan polymer. In one 
embodiment, the hydrophilic dispersing agent is a polymer 
other than chitosan having repeating structural units, wherein 
each of the structural units includes one or more carboxyl 
groups. In a particular embodiment, the hydrophilic dispers-
ing agent comprises polyglutamic acid (PGA) or any struc-
tural analogues or derivatives thereof. The advantages of uti-
lizing PGA as the hydrophilic dispersing agent include the 
a particular embodiment, the at least one ligand comprises an 30 
active agent, a targeting agent, and a hydrophilic dispersing 
agent. As discussed above, the active agent may comprise a 
STAT-3 inhibitor, the targeting agent comprises folate, and 
the hydrophilic dispersing agent comprises polyethylene gly-
col (e.g., mPEG). 
Further, in one embodiment, the method further comprises 
providing a coating of dihydrolipoic acid (DHLA) about the 
inorganic core to connect/link the Qdots to the iron oxide 
core. In some embodiments, the method further comprises 
modifying at least one of the active agent, the targeting agent, 40 
and the hydrophilic dispersing agent with N-Acetyl-L-Cys-
teine to increase dispersability and multifunctionality of the 
nanoprobe. A specific process for making optically activat-
able nanoprobes as described herein is set forth in the 
example below. 
35 fact that PGA is a negatively charged biocompatible and 
biodegradable natural polymer, rendering it suitable for in 
vivo applications. Similarly, PGA increases the overall 
hydrophilicity of the chitosan-based nanoparticles, thus 
improving the stability of the nanoparticles having PGA 
therein at physiological pH conditions (e.g., pH 7.4). Further, 
PGA provides additional functional groups to incorporate 
additional functionality and/or modalities to the nanopar-
ticles, such as the attachment of imaging agents, targeting 
agents, and/or further active agents to the nanoparticles. Even 
45 further, the incorporation of PGA in the nanoparticles will 
reduce the positive surface charge on each of the nanoparti-
cle's surface (relative to a chitosan-based nanoparticle with-
out the PGA), which will likely aid in reducing non-specific 
In accordance with another aspect of the present invention, 
there is provided another embodiment of a multi-modal, 
multi-functional nanoparticle (hereinafter DNCP or DNCPs) 
that allows for enhanced in vivo efficacy of active agents, as 
well as allows for the improved non-invasive in vivo bio- 50 
imaging. In one embodiment, the DNCPs comprise an opti-
cally activatable nanoprobe having a core component. In this 
embodiment, the core component comprises a quantum dot 
core and at least one ligand linked to the quantum dot core. In 
this embodiment, the DNCPs differ from the above-described 55 
nanoparticles in that the Qdot itself comprises the nanopar-
ticles' core rather in contrast to the inorganic core described 
above having a plurality of satellite Qdots surround an inor-
ganic core. A number of different chemical entities may be 
linked to the DNCPs, such as active agents, imaging agents, 60 
and targeting agents according to the same structures and 
methods described above. 
In one embodiment, at least one active agent, e.g., a NAC-
modified STAT3 inhibitor, is linked to the Qdot core by a 
disulfide bond, for example. In this way, when the STAT3 65 
inhibitor is linked to the Qdot core, the STAT3 drug attach-
ment to the Qdot surface will substantially quench Qdot fluo-
uptake by cells. 
Alternatively, the hydrophilic dispersing agent may com-
prise or further comprise any other compound that will 
increase the hydrophilicity of the DNCPs relative to a nano-
particle without the hydrophilic dispersing agent. In other 
embodiments, for example, the hydrophilic dispersing agent 
may comprise one or more ofNAC, glutathione, PEG (poly-
ethylene glycol), m-PEG, PPG (polypropylene glycol), 
m-PPG, polysialic acid, polyaspartate, polylysine, poly-
ethyeleneimine, biodegradable polymers (e.g., polylactide, 
polyglyceride ), and functionalized PEG, e.g., terminal-func-
tionalized PEG, analogues, derivatives, or combinations 
thereof of the above compounds. Optionally, a cross-linking 
compound may be provided to conjugate the amine groups of 
the chitosan polymer and the carboxyl groups of the hydro-
philic dispersing agent together. 
The at least one ligand linked to the Qdot may comprise an 
active agent, a targeting agent, a hydrophilic dispersing agent, 
an imaging agent, any other desired compound, and combi-
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nations thereof. In one embodiment, the biologically active 
agent, targeting agent, and/or imaging agent are linked to the 
Qdot core via thiol groups on the Qdot surface. In another 
embodiment, the biologically active agent, targeting agent 
and/or imaging agent may be linked to the chitosan-based 5 
shell, e.g., to either or both of the chitosan polymer and the 
hydrophilic dispersing agent. It is contemplated that the addi-
tional ligands described herein may be linked to the chitosan 
polymer by bonding, covalent or otherwise, through the 
amine groups of the chitosan polymer, although the invention 10 
is not so limited. When the chitosan-based shell comprises 
PGA, the respective ligand may be bonded to the hydrophilic 
dispersing agent through compatible functional groups on the 
hydrophilic dispersing agent. For example, when the hydro-
philic dispersing agent is PGA, the additional ligand may be 15 
bonded to the PGA polymer through its amine or carboxyl 
functional groups. In some embodiments, spacer molecules 
or coupling agents may be utilized between the ligand to be 
attached and the chitosan polymer or the hydrophilic dispers-
ing agent to provide the linkage between the ligand and the 20 
other substrate. 
20 
ZnS. To the Qdot surface, there is attached a N-acetylcysteine 
(NAC)-modified STAT-3 inhibitor. N-acetylcysteine acts a 
Qdot surface passivator, as well as a linker between the 
STAT-3 inhibitor and the Qdot core through its carboxyl 
and/or thiol groups. 
The chitosan-based shell comprises chitosan polymer 
(commercially available; had a measured molecular 
weight=approximately 5.3x105 Da; a degree of acetyla-
tion=77) and PGA (commercially available, MW approxi-
mately 4130 Da, biocompatible/biodegradable ). The chitosan 
polymer includes a plurality of amine groups, which will 
interact by electrostatic or charge attraction (or otherwise) 
with the carboxyl groups of the PGA to form an entangled 
network of the two polymers. In the embodiment shown, the 
PGA and chitosan polymer are cross-linked using a water-
soluble carbodiimide cross-linker (1-Ethyl-3-(3-dimethy-
laminopropyl)carbodiimide) (EDC). Alternatively, any other 
cross-linking compound may be utilized. EDC coupling con-
jugates the amine groups of the chitosan polymer and the 
carboxyl groups of the PGA together forming an amide bond. 
In the illustrated embodiment of FIG. 14, two imaging 
agents (Alexa Fluor® 660 and Gd-DOTA) are bonded to the 
chitosan polymer. Alexa Fluor® 660 is a commercially avail-
able, amine-reactive, near infrared (NIR)-emitting fluores-
The active agent, imaging agent, hydrophobic dispersing 
agent, and the targeting agent may be any compound as 
described or defined herein. Further, in any embodiment, the 
active agent, imaging agent, hydrophobic dispersing agent, 
and the targeting agent may be activatable as define herein. In 
one embodiment, the active agent is a STAT3 inhibitor, such 
as one or more of BP-1-102, SF-1066 and S31-201, all of 
which have proven activity against STAT3 with IC50 values of 
6.8, 35, and 86 µm, respectively. FIG. 15 shows the structure 
ofBP-1-102, for example. As mentioned above, the STAT3 
inhibitor may be NAC-modified. FIG. 16 illustrates an exem-
plary NAC-modified STAT3 inhibitor. 
25 cent dye (MW approximately 1300; wavelength of absorption 
and emission band maxima are 663 nm and 690 nm, respec-
tively; molar extinction coefficient 132,000 cm-1 M-1). Gd-
DOTA is a commercially available amine-reactive paramag-
netic Gd-chelate complex, which is typically used as a MRI 
30 Tl contrast agent. In addition, to the chitosan polymer, there 
is bonded a folate targeting agent having both amine and 
carboxyl functional groups. 
In one embodiment, the DNCPs of FIG. 14 may be synthe-
sized by forming three different W /0 microemulsions (ME-I, The imaging agent may comprise one or more of a fluoro-
phore, iohexy 1, and a paramagnetic chelate having a paramag-
netic ion bound therein. In one embodiment, either or both of 
the hydrophilic dispersing agent and the chitosan polymer 
may be labeled with a fluorophore. In another embodiment, 
either or both of the hydrophilic dispersing agent and the 
chitosan polymer may be labeled with a fluorophore and also 
a paramagnetic chelate (chelator) having an MRI (magnetic 
resonance imaging) contrast agent bound therein linked to the 
chitosan polymer so that the recovered stabilized chitosan-
based nanoparticles are effective as a bimodal agent that is 
fluorescent as well as paramagnetic. The MRI contrast agent 
may comprise a paramagnetic ion selected from one or more 
of gadolinium, dysprosium, europium, and compounds, or 
combinations thereof, for example. In one embodiment, the 
paramagnetic ion comprises a gadolinium ion and the chela-
35 ME-II and ME-III). Each microemulsion comprises an oil, a 
surfactant, and an aqueous phase having a chitosan polymer. 
Each microemulsion, however, includes a different aqueous 
phase. The ME-1 aqueous phase comprises Qdots, NAC-
conjugated STAT-3 inhibitor (NAC-Drug) and chitosan poly-
40 mer. The aqueous phase of ME-II will contain two compo-
nents, Alexa Fluor® 660 NIR dye conjugated to chitosan 
polymer (chitosan-dye) and DOTA-Gd (III) conjugated-chi-
tosan polymer (chitosan-DOTA-Gd). The ME-III aqueous 
phase will contain EDC cross-linker and folate-conjugated 
45 PGA (PGA-folate) and PGA polymer. In an exemplary 
embodiment, an ME composition contains 6.0 mL Triton 
X-100 (neat), cyclohexane (11.0 mL), n-hexanol ( 4 mL), and 
4.0 mL water (i.e. aqueous phase). It is noted that ME-I, 
tor is a DOTA-NHS ester (2,2',2"-(10-(2-(2.5-dioxopyrroli- 50 
din-1-yloxy )-2-oxoethyl)-14, 7, 1 O-tetraazacyclododecane-1, 
4,7-tryl)triaceticacid). Gd3 + ions are paramagnetic and 
DOTA is a chelator of Gd ion. The Gd-DOTA is paramagnetic 
agent and it provides MRI contrast. Gd-DOTA is commer-
cially available under the brandname ProHance® (also called 55 
Gadoteridol). In another embodiment, either or both of the 
chitosan polymer or the hydrophilic dispersing agent may be 
solely or additionally linked with iohexyl such that the recov-
ered nanoparticles are radio-opaque. 
A particular embodiment of a DNCP having a Qdot core 60 
and a chitosan-based shell is shown in FIG. 14. It is appreci-
ated that the illustrated embodiment is merely exemplary and 
that the nanoparticles may include more or less chemical 
entities than shown, or may comprise entirely different 
chemical entities. In the illustrated embodiment, the DNCP 65 
comprises a Qdot core, which may be any quantum dot mate-
rial as described above, such as CdS:Mn/ZnS or ZnS:Mn/ 
ME-II and ME-III vary with respect to their aqueous phase 
contents. 
The surfactant may be any suitable surfactant known in the 
art. In particular embodiments, the surfactant comprises a 
non-ionic surfactant, such as Triton X-100 (e.g., an octylphe-
nol ethylene oxide condensate (P-octyl polyethylene glycol 
phenyl ether)), available from Union Carbide, USA. Alterna-
tively, the surfactant may be any other suitable surfactant 
material, such as a fatty acid ester, a polyglycerol compound, 
a polyoxyethylene surfactant, e.g., asBrij-30, Brij-35, Brij-
92, Tween-20, and/or Tween-80. 
In one embodiment, the microemulsions may also com-
prise a co-surfactant. In a particular embodiment, the co-
surfactant comprises n-hexanol. N-hexanol is believed to sta-
bilize the interface between oil and water along with the 
primary surfactant. In another embodiment, the co-surfactant 
comprises sodium bis(2-ethylhexyl) sulfosuccinate ( docu-
sate sodium), also sold commercially as Aerosol® OT (AOT). 
The oil may be any hydrophobic compound, such as one that 
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is immiscible with water, e.g., aliphatic and aromatic hydro-
carbons.Non-limiting examples of suitable oils for use in the 
present invention, e.g. in the first and second microemulsions, 
include aliphatic and aromatic hydrocarbons, e.g., hexane, 
heptane, cyclohexane, toluene and benzene. In a particular 
embodiment, the oil comprises cyclohexane. The water 
(aqueous phase) to surfactant molar ratio may be any suitable 
ratio appropriate for the particular materials and application, 
such as from about 2:1 to about 70:1, and in a particular 
embodiment about 22: 1. 
To form the DCNPs, ME-II was added to ME-1 followed 
by addition of ME-III to the mixture. In ME-I, Qdots will be 
covalently conjugated to NAC-Drug and the resulting conju-
gate will be coated with chitosan polymer (DNCP core). The 
ME-II aqueous components will further coat Qdots and pro-
tect drugs. EDC will cross-link chitosan and PGA polymers, 
forming a stable polymeric shell (DNCP shell). Due to the 
confined environment of the water droplets, the resulting 
DCNP size is expected to be about 30 nm. 
The produced DNCPs may offer one or more of the fol-
lowing advantages: (i) imageable by both MRI and NIR 
modalities; (ii) targetable to tumor cells over-expressing 
folatereceptors; (iii) therapeutic as it carries Stat3 SMI (small 
molecule inhibitor drugs); (iv) particles are highly hydro-
philic and stable in phosphate buffer due to their hybrid nature 
(chitosan-PGA); (v) biocompatible and stable (cross-linked) 
DNCP shell structure (biodegradation rate is expected to be 
quite slow due to cross-linking); (vi) non-heavy metal based 
DNCP core when non-cadmium based ZnS:Mn/ZnS core is 
selected; (vii) Improved FRET performance is expected for 
CdS:Mn/ZnS Qdots over ZnS:Mn/ZnS Qdots (as CdS:Mn/ 
ZnS Qdots is excited efficiently at longer wavelength); (viii) 
DNCP with CdS:Mn/ZnS core may not exhibit cytotoxicity 
as the core is well protected by the cross-linked DNCP shell; 
and (ix) hundreds ofSMis (small molecule inhibitors) will be 
captured in a single particle and they will remain protected 
from the adverse extra-cellular environment. 
The DNCPs are also porous and hydrophilic particles. 
When the particles are administered to a subject, and there-
after internalized and exposed to the cytosolic glutathione 
(GSH) environment, the disulfide bond between the active 
agent and the Qdot may be cleaved by GSH, resulting in the 
release of the active agent. The rate of release of the active 
agent will depend on several factors, including the diffusion 
rate of glutathione, concentration of intra-cellular glu-
tathione, interaction of drug to polymeric shell, and the like. 
It is highly feasible to establish a sustained drug release 
mechanism by controlling the thickness of the DNCP shell 
and degree of cross-linking. 
The Qdot fluorescence in the DNCP will be quenched due 
to an electron transfer process between the nanoparticles' 
Qdot core and the Qdot's ligands, e.g., active agents. The 
restoration of Qdot emission will occur once drugs are 
released from Qdot surface upon interaction with intra-cellu-
lar glutathione. In one embodiment, the Qdot and the Alexa 
Fluor® 660 are present together in the same nanoparticle and 
are purposely selected to form a FRET pair where the Qdot 
will serve as a donor ( 600 nm emission) and the Alexa Fluor® 
660 (663 nm excitation and 690 nm emission maxima) will 
serve as an acceptor. In absence of glutathione, Qdot emission 
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nm) may be directly correlated to the total amount of drugs 
present in DNCPs (actual concentration of drugs can be quan-
tified by treating DNCPs with excess amount glutathione and 
measuring drug fluorescence). 
It is appreciated that measure of emission intensities at 
Alexa Fluor® 660 and Qdot peak emission wavelengths is 
expected to be appropriate to minimize spectral cross-talk 
while maximizing signal to background ratio. The ratio of 
emission intensity of Alexa Fluor® to Odot will likely 
10 increase drastically once drug is released from the DNCPs 
and FRET occurs from Qdots to Alexa Fluor®. It is noted that 
only drug molecules are expected to escape from the DNCP 
and both Qdot and Alexa Fluor® 660 will remain integrated 
within the particle in the chitosan-based shell. The amount of 
15 drug release can be quantified in solution experiments, for 
example, by constructing a calibration curve of the above 
intensity ratio versus drug concentration. This calibration 
curve can be used to estimate drug release in vivo (semi-
quantitatively). 
20 As set forth in Table 1 below, several characterization tech-
niques may be utilized to evaluate DNCPs. Without limita-
tion, these techniques include transmission electron micros-
copy (TEM), scanning electron microscopy (SEM), dynamic 
light scattering (DLS), UV-visible (UV-VIS) spectroscopy, 
25 Fourier transform infrared spectroscopy (FTIR), zeta poten-
tial, high pressure liquid chromatography-mass spectrometry 
(HPLC-MS), NMR/IR, mass spectrometry, fluorescence 
excitation and emission spectroscopy and fluorescence 
microscopy, near infrared (NIR) imaging (NIRS), and mag-
30 netic resonance (MR) imaging and spectroscopy. Exemplary 
uses for each technique with respect to the nanoprobes 
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TABLE 1 
Purposes 
1. To perform systematic photophysical 
characterization ofDNCP at different stages of 
development including characterization of drug 
loading and release 
2. To perform microscopic imaging ofDNCP 
internalized cancer cells to investigate 
localization of particles and their fate in 
intracellular environment 
3. To evaluate DNCP size and morphology 
4. To evaluate DNCP size distribution and to 
study their state of dispersion in phosphate 
buffer. 
5. To evaluate DNCP surface charge 
6. To characterize absorption ofDNCP 
7. To characterize Stat3 inhibitor, 
Qdot-NAC-Stat 3 conjugate, EDC based covalent 
coupling (cross-linking) 
8. To characterize chemical structure using 
infrared (IR) spectroscopy 
9. To characterize drug loading 
10. To characterize Stat3 inhibitor construct 
11. To perform optical based in vivo tumor 
imaging at NIR region 
is in the "OFF" state, but Alexa Fluor® emission is in the 
"ON" state when excited at 663 nm (therefore, trackable by 
NIR imaging in vivo). The quantification of drug release, for 
example, may be based on a FRET scheme with Qdot core as 
the donor and the Alexa Fluor® NIR dye as the acceptor under 65 
Qdot excitation. The ratio of emission intensity of Alexa 
Fluor® 660 (measured at 690 nm) to Qdot (measured at 600 
and spectroscopy 
12. To determine Tl, T2 and T2* for agar 
phantom embedded with DNCP loaded cancer 
cells as well as tumor tissue 
The present inventors have undertaken a successful syn-
thestis ofDNCP that comprise Qdot-STAT3 small molecule 
inhibitor (SMI) conjugates and have observed Qdot fluores-
cence quenching, SMI fluorescence quenching, Qdot and 
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STAT3 restoration upon treatment with glutathione, and 
folate receptor-mediated specific uptake as with the MMC-
NPs set forth above. Further, the present inventors have 
observed Qdot fluorescence restoration of the DCNPs in 
MDA-MB-231 cells upon interaction with the intra-cellular 
glutathione. A few exemplary benefits and uses of the DNCPs 
are further summarized in Table 2 below. 
Objectives 
i) Specific delivery 
of anticancer drugs 
to tumor cells 
ii) Promoting drug 
stability 
iii) Tracking drugs 
in vivo 
iv) Confirmation of 
drug release in 
vivo 
v) Quantification of 
drug concentration 
within tumor tissue 
vi) Monitor tumor 
size 
vii) Track tumor 
cells 




i) Via folate-receptor mediated targeting 
ii) By encapsulating drugs within DNCP core 
iii) By MRI (Gd-DOTA) and NIR (Alexa Fluor 660) 
imaging ofDNCP 
iv) Drug conjugated Qdots are in fluorescently 
quenched ("OFF") state due to 
electron/energy transfer process. Drug release 
process will restore Qdot fluorescence 
("ON" state). The "ON" state 
Qdot will tum on NIR emission of Alexa Fluor 
through fluorescence resonance energy transfer 
(FRET) process. 
v) By measuring ratio of fluorescence 
intensity of Alexa Fluor (at 690 nm) 
to Qdot (at 600 nm). The ratio will increase 
with the release of drugs from DNCP. 
vi) by measuring volume of MRI as well as 
NIR 3D image contrast volume) 
vii) By MRI and NIR imaging. High Tl 
relaxivity ofDNCP is the key and tracking 
of a few tumor cells together is feasible. 
Bright NIR emission from Alexa Fluor will 
minimize tissue scattering and 
auto-fluorescence, thus improving optical 
imaging sensitivity down to a cluster of 
tumor cells. 
viii) Again by MRI and NIR imaging. Due to 
high MRI and optical sensitivity of the 
DNCP, imaging of metastatic twnor cells is 
highly feasible. For monitoring tumor 
metastasis over a period of time, multiple 
administration ofDCNP buffer formulation 
will be required. 
According to another embodiment, the invention pertains 
to a nanoprobe comprising an inorganic core or an inorganic/ 
Qdot hybrid core. Either of these core components are asso-
ciated with an activatable active agent. In one embodiment, 
the active agent is one that will be released from the core upon 
exposure to an endogenous molecule, such as glutathione. 
The nanoprobe is also at least partially or fully encased in a 
lipid vesicle. In a more specific embodiment, the lipid vesicle 
is functionalized to promote cellular uptake. Non-limiting 
examples of functionalization, e.g., surface functionalization, 
is the linkage of folic acid and/or TAT-peptide to the lipid 
vesicle. 
A non-limiting list of other phospholipids that may be used 
to form lipid vesicles includes but is not limited to, one or 
more of hydrogenated soy phosphatidylcholine (HSPC), egg 
phosphatidylcholine (EPC), phosphatidylethanolamine (PE), 
phosphatidylglycerol (PG), phosphatidylinsitol (PI), mono-
sialogangolioside, spingomyelin (SPM), distearoylphos-
phatidylcholine (DSPC), dimyristoylphosphatidylcholine 
(DMPC), or dimyristoylphosphatidylglycerol (DM PG). In 
certain embodiments of the invention, the ratio of pharma-
ceutical agent to lipid-protein ranges from about 0.0005 to 
about 1 (w/w), more preferably about 0.0005 to about 0.5 
(w/w), more preferably about 0.001 to about 0.1 (w/w). 
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Phospholipids preferably form an important part of lipo-
somes. Phospholipids are, in their simplest form, composed 
of glycerol bonded to two fatty acids and a phosphate group. 
The resulting compound called phosphatidic acid contains a 
region (the fatty acid component) that is fat-soluble along 
with a region (the charged phosphate group) that is water-
soluble. Most phospholipids also have an additional chemical 
group bound to the phosphate. For example, ifthe phosphate 
is connected with choline; the resulting phospholipid is called 
10 phosphatidylcholine, or lecithin. Other phospholipids 
include phosphatidylglycerol, phosphatidylinositol, phos-
phatidylserine, and phosphatidylethanolamine. The fat-
soluble portions associate with the fat-soluble portions of 
other phospholipids while the water-soluble regions remain 
15 exposed to the surrounding solvent. The phospholipids of the 
cell membrane form into a sheet two molecules thick with the 
fat-soluble portions inside shielded on both sides by the 
water-soluble portions. This stable structure provides the cell 
membrane with its integrity. 
20 The components ofliposomes determine the physical char-
acteristics of the liposome. Liposomes preferably consist of 
amphipathic lipid molecules, with phospholipids being the 
major component. Most commonly, phosphatidylcholine is 
used as the primary constituent. Other lipids, including phos-
25 phatidylethanolamine, phosphatidylserine, sphingomyelin, 
glycolipids and sterols are often added. The physical charac-
teristics ofliposomes depend on pH, ionic strength and phase 
transition temperatures. The phase transition consists of a 
closely packed, ordered structure, called as the gel-state, to a 
30 loosely packed, less-ordered structure, known as the fluid 
state. The phase transition temperature (Tc) depends on the 
acyl chain length, degree of saturation, and polar head group. 
For example, the Tc of egg phosphatidylcholine with a high 
degree of unsaturation of the acyl chains and varying chain 
35 length is -15 degrees C. However, in a fully saturated dis-
tearoylphosphatidylcholine (DSPC), Tc is over 50 degrees C. 
Most liposomal formulations contain cholesterol in order to 
form a more closely packed bilayer system during prepara-
tion. Cholesterol addition to phosphatidylcholine changes the 
40 melting behavior of the bilayer, as cholesterol tends to elimi-
nate the phase transition. Cholesterol addition has a condens-
ing effect on the fluid-state bilayer and strongly reduces 
bilayer permeability. 
The fusion of lipid vesicles has been demonstrated to be a 
45 powerful approach to create a continuous and fluid lipid 
membrane on planar solid substrates. (Sackmann, E., Sup-
ported Membranes: Scientific and Practical Applications. 
Science 1996, 271, 43.) Recently, there are several reports on 
the formation of lipid bilayers on nanoparticles by the fusion 
50 of small unilamellar vesicles. (e.g., Cauda, V.; Engelke, H.; 
Sauer, A.; Arcizet, D.; Brauchle, C.; Radler, J.; Bein, T., 
Colchicine-Loaded Lipid Bilayer-Coated 50 Nm Mesopo-
rous Nanoparticles Efficiently Induce Microtubule Depoly-
merization Upon Cell Uptake. Nano Letters 10, 2484; Li, P. 
55 C.; Li, D.; Zhang, L. X.; Li, G. P.; Wang, E. K., Cationic Lipid 
Bilayer Coated Gold Nanoparticles-Mediated Transfection 
ofManimalian Cells. Biomaterials 2008, 29, 3617; or Mor-
net, S.; Lambert, O.; Duguet, E.; Brisson, A., The Formation 
of Supported Lipid Bilayers on Silica Nanoparticles Revealed 
60 by Cryoelectron Microscopy. Nano Letters 2005, 5, 281) It 
has been shown that the structure of nanoparticle-supported 
lipid bilayers is similar to that formed on planar substrates. 
The coating oflipid bilayers include the enhancement of the 
circulation time, accumulation of nanoparticles in cells and 
65 the minimization of the toxicity ofnanoparticles. 
In a specific embodiment, the invention pertains to a 
method of producing a nanoprobe encased in a lipid vesicle. 
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In a more specific embodiment, CdS:Mn/ZnS Qdots are syn-
thesized in a modular fashion following three steps. 
In a first step, unmodified (bare) Qdots are synthesized 
using a dioctyl sulfosuccinate sodium salt (AOT)/heptane/ 
water microemulsion system as described in the literature. 5 
(Santra, S.; Yang, H. S.; Holloway, P. H.; Stanley, J. T.; 
Mericle, R. A., Synthesis of Water-Dispersible Fluorescent, 
Radio-Opaque, and Paramagnetic Cds: Mn/Zns Quantum 
Dots: A Multifunctional Probe for Bioimaging. Journal of the 
American Chemical Society 2005, 127, 1656; Santra, S.; 10 
Yang, H.; Dutta, D.; Stanley, J. T.; Holloway, P. H.; Tan, W. 
H.; Moudgil, B. M.; Mericle, R. A., Tat Conjugated, Fite 
Doped Silica Nanoparticles for Bioimaging Applications. 
Chemical Communications 2004, 2810) 
In a second step, S3I drug (containing a secondary non- 15 
functional amine group) will be chemically linked to NAC 
using standard EDC (1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide, water soluble) coupling chemistry (as 
described in reference (Santra, S.; Liesenfeld, B.; Dutta, D.; 
Chatel, D.; Batich, C. D.; Tan, W. H.; Moudgil, B. M.; 20 
Mericle, R. A., Folate Conjugated Fluorescent Silica Nano-
particles for Labeling Neoplastic Cells. Journal of Nano-
science and Nanotechnology 2005, 5, 899)) to obtain the 
NAC-S3I conjugate. A 1:1 molar ratio ofNAC:S3I may be 
used to avoid the presence of excess NAC in the reaction 25 
mixture. In a previous paper, small lipid vesicles of Zwitteri-
onic 1,2-bis( tricosa-10, 12-diynoy 1 )-sn-glycero-3-phospho-
choline (DC8,9PC) were synthesized by dissolving lipid mol-
ecules in water at a concentration of 2 mg/mL. The lipid 
solution was incubated at 50 degrees C. for 3 hours and then 30 
extruded 10 times through a Nucleopore membrane using a 
Lipex extruder. FIG. l9a shows an AFM image of resulting 
vesicles. 
Lastly, the NAC-S3I conjugate is reacted with the unmodi-
fied Qdots to obtain S3I surface conjugated Qdots. The prod- 35 
uct, Qdot-S3I conjugates, may be separated from the micro-
emulsion system by thorough washing with 95% ethanol. 
These particles are then be further surface modified with a 
lipid bilayer (LB) to obtain LB coated QDot-S3I. Upon reac-
tion with intracellular GSH, the disulfide bond between the 40 
QDot core and NAC-S3I construct is cleaved, thus releasing 
the drug from the QDot surface and resulting in restoration of 
quenched Qdot fluorescence in proportion to amount of drug 
released, as schematically illustrated in FIG. 17. 
As described above, the nanorpobes may be coated with 45 
lipid bilayers through the fusion of small unilamellarvesicles. 
26 
and Lipid Exchange with a Nanoparticle-Supported Bilayer 
for Control of Surface Charge, Drug Containment, and Deliv-
ery. Journal of the American Chemical Society 2009, 131, 
7567). The resulting biosensor particles are shown in FIGS. 
l8a-b. In particular, FIGS. l8a-b shows a nanoparticle 10 
having a CdS:Mn/ZnS quantum dot core 12, to which an S3I 
inhibitor drug 14 will be covalently linked via a cleavable 
disulfide bond linkage. (a) a lipid bilayer 16 may be over-
coated on the surface of the S3I conjugated CdS:Mn/ZnS 
quantum dots. (b) the lipid bilayer may be further function-
alized with folic acid 18 as shown in FIG. l8b to target cancer 
cells that overexpress folate receptors, or with TAT peptide (a 
cellpenetrating peptide). 
In an alternative embodiment, the invention pertains to an 
activatable nanoprobe. The nanoprobe embodiment com-
prises a core component that is associated with an active 
agent. The core component may comprise an inorganic core 
component. Alternatively, the core component may comprise 
an inorganic/Qdot hybrid core. The active agent may be asso-
ciated with a linker comprising a double sulfide bond. The 
construction of the nanoprobe allows for activation of the 
active agent when exposed to an endogenous compound such 
as GSH. Thus, certain nanoprobe embodiments do not nec-
essarily incorporate the use of a Qdot or similar optically 
detectable means or structure. 
The nanoprobes, ligands and compounds described herein 
may be provided in an effective amount, namely an amount 
effective to achieve the desired result. 
The following examples are intended for the purpose of 
illustration of the present invention. However, the scope of the 
present invention should be defined as the claims appended 
hereto, and the following examples should not be construed as 
in any way limiting the scope of the present invention. 
EXAMPLE 1 
The following example more particularly describes the 
production of an exemplary quantum dot (Qdot)-iron oxide 
(I 0) based multimodal/multifunctional nanocomposite pro be 
(MM CNP) that is optically and magnetically imageable, tar-
getable, and capable of reporting on intracellular drug release 
events. 
1.1 Materials 
All the chemicals were used as received. Ferric (III) chlo-
ridehexahydrate, Ferrous (II) chloridetetrahydrate, ethylene-
diamine were purchased from Fluka. Lipoic acid and sodium 
borohydride were purchased from Sigma-Aldrich. Methyl-
PEG-12-NHS, and folic acid were purchased from Fisher 
Scientific, USA. All the other chemicals and solvents were 
also purchased from Fisher Scientific, USA. Nanopure water 
(deionized and filtered water) was used for the following 
example. Fluorescence spectra were recorded in NanoLog 
Spec Fluorimeter, Perkin Elmer. The FTIR spectra were 
recorded in a Perkin Elmer Spectrum 100. UV-Vis spectra 
were recorded in a Cary Win UV spectrometer. The low and 
high resolution electron microscopic images were taken in 
TEM JEOL 1011 and FEI Tecnai F30 TEM instruments 
respectively. 
The STAT-3 inhibitor used was an SF-1-046 drug. The 
In a specific embodiment, Zwitterionic lipid (DC8,9PC), 
positively charged lipid 1,2-dioleoyl-3-rimethylammonium-
propane (DOTAP) (FIG. 19b), and l-hexadecanoly,2-(9Z, 
12Z-octadecadienoyl)-sn-glycero-3-phosphatidylethanola- 50 
mine (PtdEtn) (FIG. 19c) is used. First, small unilamellar 
vesicles ofDC8,9PC, DOTAP and PtdEtn with diameters in 
the range of 15-50 nm are prepared by extrusion of hydrated 
lipid films through filters with a pore size at the nanometer 
scale with standard protocols. (Mayer, L. D.; Hope, M. J.; 55 
Cullis, P. R., Vesicles ofVariable Sizes Produced by a Rapid 
Extrusion Procedure. Biochimica Et Biophysica Acta 1986, 
858, 161). The lipid bilayers obtained from PtdEtn or 
DOTAP/PtdEtn mixtures can be further modified with folic 
acid or TAT-peptide by covalently linking to the amine group 60 non-phosphorylated salicylic acid-based small-molecule, 
SF-1-046, belongs to the S3I-201.1066 class of STAT3 
inhibitors31 •32 . Compounds in this class, including SF-1-046, 
are structural analogs of the previously reported lead STAT-3 
dimerization disruptor, S3I-201 33 . Consistent with the pub-
of PtdEtn. Second, the zeta potential of lipid bilayer-coated 
Qdots is measured and small unilamellar vesicles to confirm 
the fusion on Qdots. Third, the formation oflipid bilayers on 
QDots is observed with cryotransmission electron micro-
scope, which has been used in imaging the lipid bilayers on 
silica nanoparticles. (Liu, J. W.; Jiang, X. M.; Ashley, C.; 
Brinker, C. J., Electrostatically Mediated Liposome Fusion 
65 lished reports regarding the activities of the lead and the other 
members of the second generation class of compounds31 - 33 , 
GOLD computational modeling34 indicated SF-1-046 inter-
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acts with the STAT3 SH2 domain (data not shown), disrupting 
STAT3 SH2 domain:pTyr interactions, and thereby inhibits 
STAT-3 activation. SF-1-046 was prepared via previously 
published synthetic protocols31 •32 . 
1.2 Methods (Synthesis and Surface Modification of Iron 5 
Oxide Nanoparticle Cores (IONPs) by Dihydrolipoic Acid) 
Super paramagnetic iron oxide nanoparticles (IONPs) 
were prepared following a previously established protocol35 . 
28 
(W /0) microemulsions rapidly for 10-15 min. The W 0 (water-
to-surfactant ratio) value ofW /0 microemulsions were main-
tained at 10. For the growth of outer shell layer on the Mn 
doped CdS core Qdots, the Zn2+ ion containing (W/O) micro-
emulsion was added at very slow rate (1.5 mL/min) to the 
(W/O) microemulsions containing CdS:Mn. The nucleation 
and growth of a separate ZnS phase were suppressed by the 
very slow addition of the Zn2 + containing W/O microemul-
sion. The [Zn2+] to [Cd2 +] molar ratio (X0 ) was 8 for our 
study. 
1.4 Synthesis of NAC Derivatives of Folic Acid (FA), Drug 
(STAT3 Inhibitor) and Ethylenediamine (EDA). 
Folic acid, drug (STAT3 inhibitor) and ethylenediamine 
(EDA) were separately conjugated to NAC following stan-
15 dard bioconjugation techniques as described below. 
In brief, 1.0 M (1.13 g) of ferric chloride hexahydrate 
(FeCl3 .6H2 0); 0.5 M (0.415 g) ferrous (II) chloride tetrahy- 10 
drate (FeCl2 .4H2 0); 0.177 mL of 37% HCI in 4 mL of DI 
water were taken and stirred vigorously in a vortex in 15 mL 
centrifuge tube. 1.66 mL of 28-30% NH4 0H solution was 
dissolved in 31 mL of DI water in a conical flask and stirred 
vigorously for 5 min. Thereafter, the ferric chloride/ferrous 
chloride/RC! solution was suddenly added to the stirring 
ammonia solution, and the mixture was stirred again for 30 
min with 800 rpm at room temperature in a nitrogen atmo-
sphere to prevent critical oxidation. The black precipitate 
formed instantly. After complete stirring the iron oxide nano-
particles were separated by sedimentation at the bottom of the 
flask using an external neodymium magnetic field. 15 mL of 
the supernatant was decanted and then again the stirring was 
continued at 800 rpm. 80 mg oflipoic acid (LA) was added in 
a) STAT3-NAC Conjugation: A 2 mL anhydrous DMSO 
solution containing 3xl0-5 mo! of N-acetyl cysteine, 5.7x 
10-4 mo! ofEDC, and 1.5xl0-4 mo! ofNHS was stirred for 30 
min at room temperature. After this incubation, 1.5x10-5 mo! 
20 of solid STAT3 inhibitor compound (contains secondary non-
functional amine group) was added and whole solution mix-
ture was stirred for 2 h at room temperature. The reaction 
mixture was passed through 0.2 µm Whatman filter mem-
brane and the solution was then dried under vacuum. The 
20 mL chloroform and was vortexed for 20 min. This lipoic 25 
acid solution was then added to the iron oxide nanoparticle 
dispersion shortly. The lipoic acid was used to coat the iron 
oxide nanoparticles (FIG. 12). After 4 h of complete stirring, 
product was dispersed in 1 ml nano pure water (water that has 
been deionized and then filtered so that no particles greater 
than 1.0 nanometer remain). 
b) EDTA-NAC Conjugatation: Following the same proce-
dure as above for STAT3-NAC, a 2 mL anhydrous DMSO 
reaction mixture containing 1.2xl0-4 mo! of N-acetyl cys-
teine, 1.2xl0-3 mo! ofEDC, and 0.3xl0-3 mo! of NHS was 
stirred for 30 min at room temperature. After this incubation, 
1.2xl 0-3 mo! of ethylenediamine (EDTA) was added and the 
whole reaction mixture was then stirred for another 2 h at 
20 mL of methanol was added to reduce the viscosity of the 
aqueous phase and allowed the chloroform based ferrofluid to 30 
settle at the bottom of the container. The clear aqueous phase 
was first decanted and then the chloroform part was diluted 
again by 10 mL of chloroform. The chloroform residue was 
then taken in a separating funnel and washed with water to 
neutrality. The chloroform part then taken in a 50 mL conical 
vial and dried under vacuum to get the black solid powder. 
Thus, lipoic acid-coated iron oxide nanoparticles (LA-IO) 
were obtained. 
35 room temperature. Then, N2 gas was passed through it fol-
lowed by filtration through a 0.2 µm Whatman membrane. 
This solution was then dried under vacuum and the dried 
product was then dispersed in 1 ml nanopure water. 
To chemically reduce the disulfide bond of LA-IO to 
dithiol groups, 0.2 g of solid black lipoic acid was coated iron 40 
oxide nanoparticles in 50 mL of water/ethanol mixture (1: 1 ), 
then the dispersion was ultra-sonicated for 10 min, followed 
by vigorous stirring for another 20 min in ice bath. 0.2 g of ice 
cold solution of freshly prepared sodium borohydride was 
slowly added to it under vigorous stirring conditions. After 45 
complete addition of the solution, the stirring was continued 
for another 2 h. The black materials were then separated by 
sedimentation using a strong neodymium magnet and washed 
with DI water to neutrality. The material was then taken in 
choloroform and dried under vacuum to get the solid black 50 
dihydrolipoic acid coated iron oxide nanoparticles (DHLA-
IO). They were used for the next step of reaction as synthe-
sized. 
1.3 Synthesis of CdS:Mn/ZnS Quantum Dots (Qdots ). 
Dopant based core-shell CdS:Mn/ZnS nanocrystals were 55 
used in this example. The CdS:Mn/ZnS Qdots were synthe-
sized by a water-in-oil (W/O) microemulsionmethodfollow-
ing a published protocol36 . In brief, cadmium acetate dihy-
drate (Cd(CH3 C00)2 .2H20), manganese acetate 
tetrahydrate (Mn(CH3C00)2 .4H2 0), sodium sulfide (Na2 S), 60 
and zinc acetate dihydrate, metal basis (Zn(CH3 C00)2 . 
2H20) were used for the preparation ofCd
2 + and Mn2 +; s2 -; 
and Zn2+ ion-containing standard aqueous solutions. The 
aqueous solution was stirred for 15 min and then added to the 
AOT /heptane solutions to form the water-in-oil (W /0) micro- 65 
emulsions. The Mn-doped CdS core nanocrystals were 
formed by mixing (Cd2 + and Mn2+) and s2 - containing 
c) Folic Acid-NAC Conjugation: Following the same pro-
cedure as above for STAT3-NAC and EDA-NAC, 2 mL PBS 
solution containing 2.8xl0-5 mo! of folic acid, and 5xl0-5 
mo! of EDC was stirred for 30 min at room temperature. To 
this solution, 0.5 ml of the NAC-EDA complex was added. 
The resulting reaction mixture was then stirred for overnight 
in dark at room temperature. The reaction mixture was then 
passed through a 0.2 µm cut-off Millipore® membrane filter. 
This solution was then dried under vacuum and finally dis-
persed in nanopure water. 
1.5 Synthesis ofQdots Attached to Iron Oxide Nanoparticles 
(IONPs-Qdots) 
In this synthesis process, the CdS:Mn/ZnS core-shell 
quantum dots (Qdots) were extracted from the microemul-
sion solution by repeated centrifugation followed by washing 
several times with methanol and ethanol. The extracted Qdots 
were dispersible in DI water and used as extracted from 
microemulsion solution. To the 1 mL Qdots dispersion (20 
mg/mL) in water, the DHLA-coated IONP dispersion (2 
mg/mL) in 4 mL ethanol was added dropwise. After complete 
addition, the whole reaction mixture was stirred for over-
night. Thereafter, the nanoparticles were separated by a 
strong external neodymium magnet and washed several times 
with ethanol and DI water to remove the unused Qdots. In this 
way, the Qdots were attached on the surface ofIONPs through 
a DHLA linker. The attachment of Qdots on the IONP sur-
face, however, partially reduced the brightness of the Qdot 
luminescence. The IONP-Qdot composites were bright 
enough to be easily visualized under illumination by a hand-
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held 366 run multiband UV light source. Furthermore, the 
IONP-Qdot composites responded well to external magnetic 
fields. 
1.6 Surface Functionalization of IONPs-Qdots 
The 2 mg/mL IONPs-Qdots nanoparticles were taken in 5 
DMSO/ethanol ( 4: 1) mixture and stirred, as well as sonicated 
to be well dispersed. This dispersion was showing fluores-
cence under hand-held 366 run multiband UV light source. 
This dispersion was then added to a mixture of 0. 7 ml of drug 
(STAT-3)-NAC, 0.2 ml ofEDA-NAC and 0.4 ml ofFA-NAC 10 
conjugates slowly under constant vortexing and UV expo-
sure. It was observed that the previous fluorescence intensity 
of the IONP-Qdot conjugates was quenched. The reaction 
was stirred for overnight and then the whole conjugated nano-
composites were separated by a strong external neodymium 15 
magnet and washed several times with DMSO and nanopure 
water. Finally, the reaction mixture was dispersed in 1 ml of 
0.1 (M) NaHC03 solution and stirred for few minutes in dark. 
After this stirring, 5.5 mg of methyl-PEG-NHS ester was 
added to it and the whole solution was stirred for overnight. 20 
These activatable multifunctional/multimodal composite 
nanoprobes (MMCNPs) were then separated by an external 
neodymium magnet and washed several times with DPBS 
(Dulbecco' s phosphate buffered saline), and finally was taken 
30 
30 minutes. The fluorescence intensity of each sample was 
measured using a fluorescence microplate reader (PO-
LARstar Omega, BMG Labtech, Durham, N.C., USA) with 
excitation at about 485 run and emission detection at about 
530run. 
1.10 Confocal Fluorescence Microscopy 
The cells were fixed on the glass slide after 24 hrs of 
incubation with the nanoparticles, compounds (drug), and 
nanoparticles conjugated to compound. Confocal fluores-
cence miscroscopy on the cells was done with a home-built 
sample-scarming confocal microscope. The excitation source 
was 375 run pulse diode laser (PicoQuant GmbH, LDH-P-C-
375). The power used was 3nW. The laser was focused on a 
spot size of -300 run with a Zeiss lOOx Fluar objective lens 
(NA 1.3, WD 0.17 mm). The sample was raster scanned using 
a piezoelectric stage (Mad City Labs, Nano-LP! 00) to get the 
fluorescence images of the cells with the quantum dots. The 
fluorescence was detected using the avalanche photodiode 
(PerkinElmer SPCM-AQR-14). The spectra were collected 
using a spectrograph with a grating (150 g/mm, blaze: 500 
run) centered at 600 run (PI Acton SP-2156), which was 
coupled to a thermoelectrically cooled Electron Multiplying 
Charge Coupled Device (EM-CCD Andor iXon EM+ 
DU-897 BI). Spectra were collected from different spots on 
in DPBS for further use. 
1.7 Preparation of MRI Samples 
25 the cells. Each spectrum was collected with 10 sec exposure 
time and with three consecutive exposures. These spectra 
were then averaged in a home-written Matlab program 
(Mathwork Inc. Natick, Mass.). After taking 100 averaged 
Human breast cancer (MDA-MB-231), pancreatic cancer 
(Pane-I), and mouse thymus stromal epithelial (TE-71) cells 
have all been previously reported31 •32 . Cells were grown in 
Dulbecco's modified Eagles's medium (DMEM) containing 30 
10% heat-inactivated fetal bovine serum. Cells were treated 
spectra, they spectra were compiled and an ensemble spec-
trum was built in Matlab program. The corresponding bright 
field images were taken by using the same spectrograph with 
grating (1200 g/mm, blaze: mirror) centered at 4 run and 
coupled with EM-CCD. The exposure time for bright field 
image was 0.05 sec. 
with the nanoparticles set forth in section 1.6 above at a 
concentration of 0.1 mg/ml for 24 hours The medium was 
extracted by vacuum, and cells were washed by 1 xPBS buffer 
for 6 times to remove the unbound nanoparticles. Cells were 
detached by Trypsin with 0.25% EDTA, centrifuged down at 
1500 rpm for 3 minutes and then discarded supernatant. Cells 
were then resuspended in sterile water and mixed with equal 
volume 3xPBS and 3% agarose, and carefully poured into 10 
mm NMR tubes. Positive control was prepared by mixing 0.3 
mg/ml nanoparticles solution with equal volume of 3xPBS 
and 3% agarose. 
35 1.11 UV-Vis and Fluorescence Measurements 
The UV-Vis absorption spectra were collected by using 1 
cm path length quartz cuvette with an Agilent 8453 spectrom-
eter. The fluorescence emission spectra were taken by using 
the 1 cm path length quartz cuvettes with a N analog™ Horiba 
1.8 Magnetic Resonance Imaging 
40 Jobin Yvon fluorometer. The excitation and emission slits 
were 5 run. The excitation wavelength was 375 run for quan-
tum dots and 300 run for the drug (STAT3 inhibitor (SF-1-
046, drug). 
In 2 mL of PBS, 100 µL quantum dots in PBS were added Magnetic resonance imaging of a layered cell phantom was 
performed at 14T magnetic field strength using Paravision 
3.0.2 software and a 10 mm microimaging coil (Bruker). A 
three-dimensional gradient echo scan sequence (FLASH) 
was acquired with following settings; repetition time (TR)= 
200 ms, echo time (TE)=2.7 ms, 128x128x128 matrix size 
and field of view (FOV)=10x10x20 mm3 . Hypointense signal 
from clusters of iron oxide containing cells, was inverted and 
assigned a red pseudocolor for image presentation on subse-
quent 3D renderings performed using OsiriX viewing soft-
ware (http://www.osirix-viewer.com). 
45 and the absorption and emission was taken. Thereafter, 50 µL 
of 0.3 M solution of GSH was added and absorption and 
emission spectra were collected immediately after addition of 
GSH and after every 5 min up to 60 min. This gave a plot of 
"-max emission vs. time in min. After 35 min, the fluorescence 
50 was nearly constant showing that the drug is completely 
released after 35 min. 
1.9 CyQUANT™ Cell Proliferation Assay 55 
Human breast cancer (MDA-MB-231) cells, mouse thy-
mus epithelial stromal (TE-71) cells, and pancreatic cancer 
(Pane-I) cells were grown in Dulbecco's modified Eagles's 
medium (DMEM) containing 10% heat-inactivated fetal 
bovine serum. 5000 cells per well were cultured in 96-well 60 
plates. The cells were treated with nanoparticles, compounds 
(drug), and nanoparticles conjugated to compound for 24 
hours. Cyquant cell proliferation assays (Invitrogen Corp/ 
Life Technologies Corp, Carlsbad, Calif.) were then per-
formed on each microplate well. The medium was removed 65 
by vacuum, and 50 µL 1 x dye binding solution were added to 
each mi crop late well, which were then incubated at 3 7° C. for 
EXAMPLE2 
In this example, two different water-soluble biomolecules, 
the N-acetyl cysteine (NAC) and the glutathione (GSH), were 
used as surface coating ligands for the Qdot nanoparticles. 
This includes a single-step, one-part synthesis where the Qdot 
nanocrystals were grown in the presence of the biomolecules. 
These Qdots were characterized by fluorescence spectros-
copy. Stability of the GSH-coated Qdots and the NAC-coated 
Qdots were studied by treating the coated Qdots with ethyl-
enediaminetetraacetic acid (EDTA, a strong chelating agent 
for Zn and Cd ions). The results show that fluorescence prop-
erties of Qdots are affected by the type of surface coated 
ligands. In comparison to the GSH-coated Qdots, the NAC-
coated Qdots show broad, but strong emission towards near 
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infra-red region. When treated with EDTA, the fluorescence 
property of the GSH-coated Qdot was affected less than the 
NAC-coated Qdots. This preliminary study shows that NAC-
coated Qdots could thus potentially be used to develop acti-
vatable ("OFF/ON") probes for potential deep-tissue imaging 5 
applications, the GSH-coated Qdots could thus be applied for 
probing desired analytes or for bioimaging purposes in envi-
ronmentally harsh conditions. 
2.1 Preparation ofGSH-Coated Qdots 
A water-in-oil (W/O) microemulsion technique was used 10 
to synthesize GSH-coated CdS:Mn/ZnS Qdots at room tem-
perature. The W/O microemulsion system consisted of dio-
ctyl sodium sulfosuccinate (called Aerosol OT or AOT-a 
surfactant), heptane (oil) and water (as an aqueous phase). 
Acetate salts of bivalent cadmium, zinc and manganese were 15 
using as an ionic source. In a typical procedure, three separate 
aqueous stock solutions containing acetate salts were pre-
pared using DI water first; Solution A-10.0 mL aqueous 
solution containing cadmium acetate dihydrate (258.5 mg), 
7.4 mg manganese acetate tetrahydrate and 15 mg of GSH; 20 
Solution B-5.0 mL aqueous solution containing 257.5 mg 
sodium sulfide and Solution C-5 mL aqueous solution con-
taining 285.3 mg zinc acetate dihydrate. Next, 35 mL of AOT 
stock solution was prepared by dissolving 4.46 g of AOT in 
heptane under magnetic stirring for about 30 mins. Then, 25 
solution Al was prepared by mixing 0.18 mL of stock Solu-
tionA with 5 mL of AOT/heptane solution, Solution Bl was 
prepared by mixing 0.54 mL of stock Solution B with 15 mL 
of AOT/heptane solution and Solution Cl was prepared by 
mixing 0.54 mL of stock Solution C with 15 mL of AOT/ 30 
heptane solution. 
Solutions Al, B 1 and Cl were then magnetically stirred for 
1 hour. Solution Al was then added to Solution Bl and the 
resulting mixed solution (Solution AB 1) was stirred magneti-
cally for 15 mins. SolutionABl was addeddropwise (using a 35 
burette) at a rate 2-3 mL per min to the Solution Cl under 
magnetic stirring. To obtain maximum brightness from 
Qdots, this solution mixture should be stirred for 7 days at the 
room temperature. The GSH-coated CdS:Mn/ZnS Qdots 
were then isolated from the W /0 microemulsion system after 40 
precipitating them first using 95% ethanol, followed by 
repeated washings ( 6-7 times) with ethanol and ethanol-water 
mixture to remove surfactants, any un-reacted ions and excess 
GSH. Ultra-centrifugation technique was used between two 
successive washing steps to isolate GSH-Qdots in the pellet 45 
form from the solution. The NAC-coated Qdots were simi-
larly prepared by adding 15 mg of NAC in Solution A (in 
place of 15 mg GSH). All the chemicals, reagents and sol-
vents were purchased from Aldrich-Sigma and used without 
any further purification. The Barnstead Nanopure DI water 50 
was used to prepare all the aqueous solutions. Both GSH-
Qdots and NAC-Qdots were dispersed well in DI water. 
2.2. Fluorescence Study 
32 
zinc and cadmium ions. The GSH-Qdot fluorescence is how-
ever quenched by the copper ions. FIG. 21 shows the effect of 
increase of Cu ion concentration on the fluorescence intensity 
ofGSH-Qdots. A steady decrease in the fluorescence inten-
sity was observed with the increase in the Cu ion concentra-
tion. The inset of the FIG. 21 shows the linear relationship 
between the fluorescence intensity and the Cu ion concentra-
tion. While not wishing to be bound by theory, our results 
suggest that Cu ions are possibly reacting with the Qdots, 
forming copper sulfide on the Qdot surface. Due to this 
chemical transformation the microenvironment of Mn is 
altered, resulting in the creation of surface related defects. 
Such defects could result in the increase of non-radiative 
processes and fluorescence quenching. 
2.4 Preparation ofNAC-Qdots 
The NAC-coated Qdots are highly soluble in DI water and 
they exhibit extremely bright fluorescence properties. A very 
broad fluorescence emission in the range 525 nm -800 nm was 
observed. This broad emission could have been originated 
due to NAC-induced surface-related defects. FIG. 22 shows 
the effect of increase of EDTA concentration on the fluores-
cence intensity ofNAC-Qdots. A steady decrease in the fluo-
rescence intensity was observed upon increase in the concen-
tration ofEDTA. This observation suggests that NAC-Qdot is 
not stable against the EDTA chelator. The fluorescence 
quenching could be due to direct binding of EDTA to the ZnS 
surface and/or replacement of the NAC by the EDTA. It is 
well known that EDTA forms a stable complex with Zn ions. 
A similar observation (i.e. steady decrease in the fluorescence 
intensity) was made when the NAC-Qdot was exposed to the 
increasing concentration of Cu ions (FIG. 23). This may be 
attributed to the formation of Cu sulfide on to the Qdot sur-
face. 
In summary, we have described a simple but robust method 
of making water-soluble CdS:Mn/ZnS at the room tempera-
ture. Both the GSH and the NAC are capable of coating Qdot 
surface via conjugation through their sulfhydryl (-SH) 
groups and thus forming hydrophilic Qdots. The GSH Qdots 
are more stable than NAC-Qdots when challenged against a 
strong chelator, EDTA. The Cu ions are able to quench fluo-
rescence of both the GSH-Qdot and the NAC-Qdot, suggest-
ing the formation of copper sulfide on to the Qdot surface. The 
NAC-Qdot emission band is broader than the GSH Qdots. 
Therefore, NAC-Qdots may be used for NIR imaging of 
biological tissues using two-photon excitation. Our study 
suggests that NAC-Qdots could be an attractive choice for the 
fabrication of activatable ("OFF/ON") Qdots for bioimaging 
and sensing applications. 
While various embodiments of the present invention have 
been shown and described herein, it will be obvious that such 
embodiments are provided by way of example only. Numer-
ous variations, changes and substitutions may be made with-
out departing from the invention herein. Accordingly, it is 
intended that the invention be limited only by the spirit and Both GSH-Qdot and NAC-Qdot exhibited bright yellow 
emission when exposed to a hand-held UV illumination. 
2.3. Excitation ofGSH-Qdots 
55 scope of the appended claims. 
The GSH coated Qdots emits at-620 nm upon excitation at 
3 7 5 nm. In comparison to the NAC-Qdot, the GSH-Qdots are 
moderately bright. FIG. 20 shows the effect of increase of 
EDTA concentration on the fluorescence intensity of GSH- 60 
Qdot in DI water at the room temperature. No significant 
change in the fluorescence intensity was observed. Initially, 
there was a slight quenching (i.e. decrease in the fluorescence 
intensity) followed by restoration of fluorescence intensity to 
its initial value. This data suggest that EDTA has minimal 65 
effect on the stability of GSH-Qdots, even though EDTA is 
known to form stable water soluble complex with both the 
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6. The optically activatable nanoprobe of claim 5, wherein 
the quantum dot comprises a coating of the hydrophilic dis-
persing agent. 
7. The optically activatable nanoprobe of claim 1, wherein 
the hydrophilic dispersing agent comprises at least one of 
N-acetyl cysteine and glutathione. 
8. The optically activatable nanoprobe of claim 1, wherein 
the at least one ligand is linked to the quantum dot by 
N-Acetyl-L-Cysteine. 
9. The optically activatable nanoprobe of claim 1, wherein 
the inorganic core comprises iron oxide, and wherein the 
quantum dot comprises a CdS:Mn/ZnS quantum dot. 
10. The optically activatable nanoprobe of claim 1 
~he_rein the quantum dot is linked to the inorganic core by ~ 
hnkmg group, and wherein the linking group comprises a 
hetero-bifunctional cross-linking molecule. 
11. The optically activatable nanoprobe of claim 10, 
wherein the linking group comprises dihydrolipoic acid. 
12. The optically activatable nanoprobe of claim 1 
wherein the at least one ligand is linked to the quantum dot b; 
a disulfide bond. 46. Banerjee, S., Kar, S., Perez, J.M. & Santra, S. Quantum 
Dot-Based OFF/ON Probe for Detection of Glutathione. 
The Journal of Physical Chemistry C 113, 9659-9663, 
doi:10.1021/jp9019574 (2009). 
47. Mitra, R. N. et al. An activatable multimodal/multifunc-
tioi:al nanoprobe for direct imaging of intracellular drug 
delivery. Biomaterials 33, 1500-1508, doi:l0.1016/j.bio-
materials.2011.10.068 (2012). 
13. The optically activatable nanoprobe of claim 1 
wherein the nanoprobe has a particle size of from 20-40 nm'. 
25 
. 14. An optically activatable nanoprobe for monitoring 
mtracellular drug delivery comprising: 
a core component; and 
at least one ligand linked to the core component, the at least 
one ligand comprising at least one of an active agent, a 
~argeting agent, an imaging agent, a hydrophilic dispers-
mg agent and combinations thereof, the at least one 
ligand being effective to reduce luminescence of the of 
the quantum dot when linked thereto. 
The present application further cross-references US Pub- 30 
lished Patent Application Nos. 20110021745, 20100254911, 
20100254911, 20070269382, 20070264719, 20060228554, 
each of which is incorporated by reference herein 
15. The optically activatable nanoprobe of claim 14 
35 
wherein the core component comprises an iron oxide core and 
a plurality of quantum dots linked to the inorganic core. 
The invention claimed is: 
1. An optically activatable nanoprobe comprising: 
an inorganic core; 
a quantum dot linked to the inorganic core; and 16. The optically activatable nanoprobe of claim 14, 
wherein the core component comprises a quantum dot. at least one ligand linked to the quantum dot, the at least 
one ligand effective to reduce luminescence of the quan-
tum dot when linked thereto. 
2. The optically activatable nanoprobe of claim 1, wherein 
the at least one ligand comprises at least one of an active 
~gen~, a targeting agent, a hydrophilic dispersing agent, an 
1magmg agent, or combinations thereof. 
17. The optically activatable nanoprobe of claim 14 
40 
wherein the core component comprises a quantum dot and ~ 
chitosan polymer. 
3. The optically activatable nanoprobe of claim 2, wherein 45 
the at.least one ligand comprises each of an active agent, a 
targetmg agent, and a hydrophilic dispersing agent. 
4. The optically activatable nanoparticle of claim 3 
wherein the active agent comprises a STAT-3 inhibitor th~ 
targeting agent comprises folate, and the hydrophilic dis;ers- 50 
ing agent comprises polyethylene glycol. 
5. The optically activatable nanoprobe of claim 1, wherein 
the at least one ligand comprises a hydrophilic dispersing 
agent. 
18. The optically activatable nanoprobe of claim 17 
wherein the chitosan polymer further comprises a hydrophili~ 
dispersing agent. 
19. The optically activatable nanoprobe of claim 14, fur-
~her comprising a lipid vesicle at least partially or fully encas-
mg the core component and the at least one ligand. 
20. The optically activatable nanoparticle of claim 14 
wher~in the at least one ligand comprises an active agent, ~ 
targetmg agent, and a hydrophilic dispersing agent, wherein 
the active ag.ent comprises a STAT-3 inhibitor, the targeting 
agent compnses folate, and the hydrophilic dispersing agent 
comprises polyethylene glycol or derivatives thereof. 
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